Engineered guide RNAs and polynucleotides for RNA editing targeted to LRRK2

Genetically engineered guide RNAs with specific structural features enhance RNA editing efficiency and specificity for LRRK2 RNA, addressing the limitations of current technologies and offering therapeutic potential for diseases associated with LRRK2 mutations.

JP2024543208AInactive Publication Date: 2024-11-19SHAPE THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024532770
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-10-26
Filing Date
2022-11-30
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current technologies lack efficient methods for targeted RNA editing of LRRK2 RNA, which is associated with various diseases, particularly Parkinson's disease and Crohn's disease, due to limitations in RNA editing specificity and efficacy.

Method used

Genetically engineered guide RNAs with specific structural features, such as mismatches, bulges, and internal loops, are designed to enhance the activity of RNA editing entities like ADAR1 and ADAR2, facilitating precise editing of LRRK2 RNA by forming guide-target RNA scaffolds that promote adenosine deamination.

Benefits of technology

The engineered guide RNAs significantly increase the editing efficiency and specificity of LRRK2 RNA, potentially correcting disease-associated mutations and providing therapeutic benefits for conditions like Parkinson's and Crohn's disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024543208000001_ABST
    Figure 2024543208000001_ABST
Patent Text Reader

Abstract

Disclosed herein are potential engineered guide RNAs targeting LRRK2 and compositions comprising the same for treating a disease or condition (e.g., Parkinson's disease) in a subject. Also disclosed herein are methods of treating a disease or condition (e.g., Parkinson's disease) in a subject by administering the potential engineered guide RNA or pharmaceutical composition described herein.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority under 35 U.S.C. § 119 to Provisional Application No. 63 / 284,738, filed December 1, 2021, Provisional Application No. 63 / 327,381, filed April 5, 2022, and Provisional Application No. 63 / 419,436, filed October 26, 2022, the disclosures of which are incorporated by reference in their entireties herein. Summary of the Invention

[0002] Provided herein is an engineered potential guide RNA, wherein (a) upon hybridization to a sequence of a target LRRK2 RNA, it forms a guide-target RNA scaffold with the sequence of the target LRRK2 RNA, (b) the formation of the guide-target RNA scaffold substantially forms a microfootprint comprising one or more structural features selected from the group consisting of a mismatch, a bulge, an internal loop, and a hairpin, (c) the structural feature is not present in the engineered potential guide RNA prior to hybridization of the engineered potential guide RNA to the LRRK2 target RNA, and (d) upon hybridization of the engineered potential guide RNA to the sequence of the target LRRK2 RNA, the engineered potential guide RNA is capable of modifying the target LRRK2 RNA by an RNA editing entity. Disclosed are engineered potential guide RNAs that promote RNA editing of an on-target adenosine in the sequence of the RNA, and (e) the engineered potential guide RNA has at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 99%, or 100% sequence identity to any one of SEQ ID NO:2-395 or SEQ ID NO:398-427. In some embodiments, the engineered potential guide RNA comprises the polynucleotide sequence of any one of SEQ ID NO:2-395 or SEQ ID NO:398-427. In some embodiments, the engineered potential guide RNA comprises at least 20-50 contiguous nucleotides from a portion of any one of SEQ ID NO:2-395 or SEQ ID NO:398-427, in some embodiments, the sequence further comprises one or more of the following: T at position -7, T at position -6, G at position -3, A at position -2, G at position -1, C at position 1, C at position 2, T at position 3, G at position 4, and T at position 10, where these positions are relative to a target adenosine in the sequence of a target LRRK2 RNA that is subject to editing by the RNA editing entity.In some embodiments, the engineered potential guide RNA comprises a cytosine that is opposite the target adenosine edited by the RNA editing entity in the guide-target RNA scaffold when the engineered potential guide RNA hybridizes to the target RNA, thereby forming an A / C mismatch in the guide-target RNA scaffold. In some embodiments, the guide-target RNA scaffold comprises a barbell macrofootprint comprising a first internal loop and a second internal loop adjacent opposite ends of the microfootprint, the first internal loop being on the 5' side of the microfootprint and the second internal loop being on the 3' side of the microfootprint, the first internal loop and the second internal loop facilitating an increased amount of editing of the target adenosine in the target RNA compared to an otherwise equivalent engineered guide RNA lacking the first internal loop and the second internal loop. In some embodiments, the first internal loop is positioned about 7 bases away from the A / C mismatch to about 30 bases away from the A / C mismatch with respect to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the first internal loop is positioned 10 bases away from the A / C mismatch with respect to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned about 18 bases away from the A / C mismatch to about 34 bases away from the A / C mismatch with respect to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned 34 bases away from the A / C mismatch with respect to the base of the second internal loop closest to the A / C mismatch.In some embodiments, the target LRRK2 RNA encodes an LRRK2 polypeptide having a mutation relative to a wild-type LRRK2 polypeptide, where the mutation is E10L, A30P, S52F, E46K, A53T, L119P, A211V, C228S, E334K, N363S, V366M, A419V, R506Q, N544E, N551K, A716V, M712V, I723V, P755L, R793M, I810V, K871E, Q923H, Q930R, R1067Q, S1096C, Q1111H, I112 2V, A1151T, L1165P, I1192V, H1216R, S1228T, P1262A, R1325Q, I1371V, R1398H, T1410M, D1420N, R1441G, R1441H, A1442P, P1446L, V1450I, K1468E, R1483Q, R1514Q, P1542S, V1 613A, R1628P, M1646T, S1647T, Y1699C, R1728H, R1728L, L1795F, M1869V, M1869T, L1870 In some embodiments, the mutation is a G2019S mutation. In some embodiments, the one or more structural features of the microfootprint include a bulge, and the bulge is a symmetric bulge. In some embodiments, the one or more structural features of the microfootprint include a bulge, and the bulge is an asymmetric bulge. In some embodiments, the one or more structural features of the microfootprint include an internal loop, and the internal loop is a symmetric internal loop. In some embodiments, one or more structural features of the microfootprint comprise an internal loop, which is an asymmetric internal loop. In some embodiments, one or more structural features of the microfootprint comprise a wobble base pair. In some embodiments, one or more structural features of the microfootprint comprise a hairpin, which is a recruiting hairpin or a non-recruiting hairpin.In some embodiments, the RNA editing entity comprises ADAR1, ADAR2, ADAR3, or any combination thereof. In some embodiments, the engineered potential guide RNA is encoded by an engineered polynucleotide. In some embodiments, the engineered polynucleotide is contained in or present on a vector. In some embodiments, the vector is a viral vector, and the engineered polynucleotide is encapsidated in the viral vector. In some embodiments, the viral vector is an adeno-associated viral (AAV) vector or a derivative thereof. In some embodiments, the AAV vector is AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, or a derivative, chimera, or variant thereof. In some embodiments, the AAV vector is a recombinant AAV (rAAV) vector, a hybrid AAV vector, a chimeric AAV vector, a self-complementary AAV (scAAV) vector, or any combination thereof.

[0003] Also provided herein is an engineered potential guide RNA, wherein (a) upon hybridization to a sequence of a target LRRK2 RNA, it forms a guide-target RNA scaffold with the sequence of the target LRRK2 RNA, (b) the formation of the guide-target RNA scaffold substantially forms a microfootprint comprising one or more structural features selected from the group consisting of a mismatch, a bulge, an internal loop, and a hairpin, (c) the structural feature is not present in the engineered potential guide RNA prior to hybridization of the engineered potential guide RNA to the LRRK2 target RNA, and (d) upon hybridization of the engineered potential guide RNA to the sequence of the target LRRK2 RNA, the engineered potential guide RNA is capable of modifying the target LRRK2 RNA by an RNA editing entity. Disclosed are engineered potential guide RNAs that promote RNA editing of an on-target adenosine in the sequence of the RNA, and (e) the sequence further comprises one or more of the following: a T at position -7, a T at position -6, a G at position -3, an A at position -2, a G at position -1, a C at position 1, a C at position 2, a T at position 3, a G at position 4, and a T at position 10, which positions are relative to a target adenosine in the sequence of a target LRRK2 RNA that is subject to editing by an RNA editing entity.

[0004] Also disclosed herein is a pharmaceutical composition comprising (a) an engineered potential guide RNA described herein, and (b) a pharma- ceutically acceptable excipient, carrier, or diluent.

[0005] Also disclosed herein is a method of treating a disease or condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an engineered potential guide RNA described herein or a pharmaceutical composition described herein. In some embodiments, the disease or condition comprises Parkinson's disease. In some embodiments, the disease or condition comprises Crohn's disease. In some embodiments, the subject is a patient with one of the following: E10L, A30P, S52F, E46K, A53T, L119P, A211V, C228S, E334K, N363S, V366M, A419V, R506Q, N544E, N551K, A716V, M712V, I723V, P755L, R793M, I810V, K871E , Q923H, Q930R, R1067Q, S1096C, Q1111H, I1122V, A1151T, L1165P, I1192V, H1216R, S 1228T, P1262A, R1325Q, I1371V, R1398H, T1410M, D1420N, R1441G, R1441H, A1442P, P1 446L, V1450I, K1468E, R1483Q, R1514Q, P1542S, V1613A, R1628P, M1646T, S1647T, Y1 699C, R1728H, R1728L, L1795F, M1869V, M1869T, L1870F, E1874X, R1941H, Y2006H, I20 The subject has a mutation in the LRRK2 polypeptide selected from the group consisting of 12T, G2019S, I2020T, T2031S, N2081D, T2141M, R2143H, Y2189C, T2356I, G2385R, V2390M, E2395K, M2397T, L2466H, and Q2490NfsX3. In some embodiments, the mutation in the LRRK2 polypeptide is associated with a disease or condition. In some embodiments, the mutation in the LRRK2 polypeptide is G2019S. In some embodiments, the subject is a human or non-human animal.

[0006] The novel features of the present disclosure are set forth with particularity in the appended claims. A further understanding of the features and advantages of the embodiments of the present disclosure will be obtained by reference to the following detailed description and the accompanying drawings which set forth illustrative embodiments. [Brief description of the drawings]

[0007] [Figure 1] A legend is shown for various exemplary structural features present in the guide-target RNA scaffold formed upon hybridization of a potential guide RNA of the present disclosure to a target RNA. Exemplary structural features shown include an 8 / 7 asymmetric loop (8 nucleotides on the target RNA side and 7 nucleotides on the guide RNA side), a 2 / 2 symmetric bulge (2 nucleotides on the target RNA side and 2 nucleotides on the guide RNA side), a 1 / 1 mismatch (1 nucleotide on the target RNA side and 1 nucleotide on the guide RNA side), a 5 / 5 symmetric internal loop (5 nucleotides on the target RNA side and 5 nucleotides on the guide RNA side), a 24 bp region (24 nucleotides on the target RNA side base-paired with 24 nucleotides on the guide RNA side), and a 2 / 3 asymmetric bulge (2 nucleotides on the target RNA side and 3 nucleotides on the guide RNA side).

[0008] [Diagram 2] A summary of how the library was generated to screen for longer self-annealing RNA structures is shown.

[0009] [Diagram 3] 1 shows a comparison of cell-free RNA editing using the high throughput described herein with intracellular RNA editing facilitated via the same engineered guide RNA sequence at various time points.

[0010] [Figure 4]Heatmap of all self-annealing RNA structures tested for four microfootprints (A / C mismatches, 2108, 871, and 919) formed within various configurations of the barbell macrofootprint. The y-axis shows all engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0011] [Diagram 5] 1 shows the LRRK2 RNA editing profile of various engineered guide RNAs of the present disclosure.

[0012] [Figure 6] 1 shows the LRRK2 RNA editing profile of engineered guide RNAs of the present disclosure that form barbell macro- and microfootprints on the guide-target RNA scaffold.

[0013] [Figure 7A] Figure 2 shows the ADAR-mediated RNA editing efficiency of machine learning designed guide RNAs targeting LRRK2 in an in-cell editing model. The guide RNAs have a barbell macro footprint with symmetric internal loops at positions -20 and +26, respectively. [Figure 7B] Figure 2 shows the ADAR-mediated RNA editing efficiency of machine learning designed guide RNAs targeting LRRK2 in an in-cell editing model. The guide RNAs have a barbell macro footprint with symmetric internal loops at positions -20 and +26, respectively. [Figure 7C] Figure 2 shows the ADAR-mediated RNA editing efficiency of machine learning designed guide RNAs targeting LRRK2 in an in-cell editing model. The guide RNAs have a barbell macro footprint with symmetric internal loops at positions -20 and +26, respectively.

[0014] [Figure 8]1 shows LRRK2-targeted RNA editing of a control engineered guide and an exemplary engineered guide 919 via ADAR1 and ADAR1+ADAR2.

[0015] [Figure 9] 1 shows LRRK2-targeted RNA editing of exemplary engineered guide 1976 and exemplary engineered guide 2397 via ADAR1 and ADAR1+ADAR2.

[0016] [Figure 10] 1 shows LRRK2-targeted RNA editing of an exemplary engineered guide 871 and an exemplary engineered guide 610 via ADAR1 and ADAR1+ADAR2.

[0017] [Figure 11] 1 shows ADAR1 and ADAR1+ADAR2 mediated LRRK2 targeted RNA editing of exemplary engineered guides designed by machine learning, ML-generated 0703 and ML-generated 0719.

[0018] [Figure 12] 1 shows LRRK2-targeted RNA editing via ADAR1 and ADAR1+ADAR2 of exemplary engineered guides designed by machine learning, ML-generated 0728 and ML-generated 0732.

[0019] [Figure 13] 1 shows LRRK2-targeted RNA editing via ADAR1 and ADAR1+ADAR2 of exemplary engineered guides designed by machine learning, ML-generated 0733 and ML-generated 0742.

[0020] [Figure 14] 1 shows ADAR1 and ADAR1+ADAR2 mediated LRRK2 targeted RNA editing of exemplary engineered guides designed by machine learning, ML-generated 0743 and ML-generated 0745.

[0021] [Figure 15] 1 shows ADAR1 and ADAR1+ADAR2 mediated LRRK2 targeted RNA editing of exemplary engineered guides, ML-generated 0766 and ML-generated 0769, designed by machine learning.

[0022] [Figure 16] 1 shows ADAR1 and ADAR1+ADAR2 mediated LRRK2 targeted RNA editing of exemplary engineered guides, ML-generated 0766 and ML-generated 0769, designed by machine learning.

[0023] [Figure 17] 1 shows LRRK2-targeted RNA editing via ADAR1 and ADAR1+ADAR2 of exemplary engineered guides designed by machine learning, ML-Comprehensive-0049 and ML-Comprehensive-0069.

[0024] [Figure 18] 1 shows LRRK2-targeted RNA editing via ADAR1 and ADAR1+ADAR2 of exemplary engineered guides designed by machine learning, ML-Comprehensive-0090 and ML-Comprehensive-0139.

[0025] [Figure 19] 1 shows ADAR1 and ADAR1+ADAR2 mediated LRRK2 targeted RNA editing of exemplary engineered guides designed by machine learning, ML-generated 0274 and ML-generated 0325.

[0026] [Figure 20] 1 shows LRRK2-targeted RNA editing of exemplary engineered guides, ML-generated 0332 and ML-generated 0559, designed by machine learning, via ADAR1 and ADAR1+ADAR2.

[0027] [Figure 21]1 shows ADAR1 and ADAR1+ADAR2 mediated LRRK2 targeted RNA editing of exemplary engineered guides, ML-generated 0639 and ML-generated 0643, designed by machine learning.

[0028] [Figure 22] 1 shows LRRK2-targeted RNA editing via ADAR1 and ADAR1+ADAR2 of exemplary engineered guides designed by machine learning, ML-generated 0644 and ML-generated 0690.

[0029] [Diagram 23] 1 shows LRRK2-targeted RNA editing of exemplary engineered guides designed by machine learning, ML-generated 0699 and ML-generated 0701, via ADAR1 and ADAR1+ADAR2.

[0030] [Figure 24] 1 shows LRRK2-targeted RNA editing via ADAR1 and ADAR1+ADAR2 of exemplary engineered guides designed by machine learning, ML-Comprehensive-0395 and ML-Comprehensive-0453.

[0031] [Diagram 25] 1 shows LRRK2-targeted RNA editing via ADAR1 and ADAR1+ADAR2 of exemplary engineered guides designed by machine learning, ML-Comprehensive0464 and ML-Comprehensive1042.

[0032] [Figure 26] 1 shows LRRK2-targeted RNA editing via ADAR1 and ADAR1+ADAR2 of exemplary engineered guides designed by machine learning, ML-generated 0002 and ML-generated 0013.

[0033] [Figure 27]1 shows ADAR1 and ADAR1+ADAR2 mediated LRRK2 targeted RNA editing of exemplary engineered guides designed by machine learning, ML-generated-0016 and ML-generated-0043.

[0034] [Figure 28] 1 shows LRRK2-targeted RNA editing of exemplary engineered guides designed by machine learning, ML-generated-0058 and ML-generated-0071, via ADAR1 and ADAR1+ADAR2.

[0035] [Figure 29] 1 shows ADAR1 and ADAR1+ADAR2 mediated LRRK2 targeted RNA editing of exemplary engineered guides designed by machine learning, ML-generated-0130 and ML-generated-0156.

[0036] [Diagram 30] 1 shows LRRK2-targeted RNA editing of exemplary engineered guides designed by machine learning, ML-generated 0176 and ML-generated 0218, via ADAR1 and ADAR1+ADAR2.

[0037] [Diagram 31] 1 shows LRRK2-targeted RNA editing via ADAR1 and ADAR1+ADAR2 of exemplary engineered guides designed by machine learning, ML-Comprehensive1045 and ML-Comprehensive1540.

[0038] [Diagram 32] 1 shows LRRK2-targeted RNA editing via ADAR1 and ADAR1+ADAR2 of exemplary engineered guides designed by machine learning, ML-Comprehensive-0315 and ML-Comprehensive-0414.

[0039] [Diagram 33]1 shows LRRK2-targeted RNA editing via ADAR1 and ADAR1+ADAR2 of an exemplary engineered guide designed by machine learning, ML-global-0013.

[0040] [Figure 34A] 1 shows the selection of two exemplary LRRK2 guide RNAs designed by machine learning for further genetic engineering. [Figure 34B] 1 shows the selection of two exemplary LRRK2 guide RNAs designed by machine learning for further genetic engineering.

[0041] [Diagram 35] A plot of the editing specificity of machine learning designed LRRK2 global guide RNAs via ADAR1, ADAR2, or ADAR1+ADAR2 is shown.

[0042] [Diagram 36] 1 shows exemplary LRRK2 global guide RNAs designed by machine learning that demonstrate specificity for ADAR2.

[0043] [Figure 37A] The top guide RNAs showing specificity for ADAR1+ADAR2 are shown. [Figure 37B] Top guide RNAs showing specificity for ADAR1+ADAR2 are shown.

[0044] [Figure 38A] The top guide RNAs that show specificity for ADAR2 are shown. [Figure 38B] The top guide RNAs that show specificity for ADAR2 are shown.

[0045] [Figure 39A] The top guide RNAs that show specificity for ADAR1 are shown. [Figure 39B] The top guide RNAs that show specificity for ADAR1 are shown.

[0046] [Diagram 40] A comparison between ML-derived gRNAs and gRNAs generated using an in vitro high-throughput screening (HTS) method is shown.

[0047] [Diagram 41] An overview of the genetic engineering of guide RNAs generated from high-throughput screening is shown.

[0048] [Figure 42A] 1 shows ADAR-mediated cell-free and intracellular editing of an exemplary LRRK2 guide 610 that does not contain a barbell macro footprint. [Figure 42B] 1 shows ADAR-mediated cell-free and intracellular editing of an exemplary LRRK2 guide 610 comprising a barbell macrofootprint.

[0049] [Figure 43A] FIG. 6 shows the genetic engineering of the macrofootprint positions of an exemplary guide 610 targeting LRRK2. The alignment of the macrofootprint positions of the exemplary guide relative to the A / C mismatch and how this alignment affects ADAR1 and ADAR1+ADAR2 mediated editing. [Figure 43B] 1 shows the genetic engineering of the macro footprint location of an exemplary guide 610 targeting LRRK2. 2 shows the percent editing of the ADAR1-mediated guide variant. [Figure 43C] 1 shows the genetic engineering of the macro footprint location of an exemplary guide 610 targeting LRRK2. 2 shows the percent editing of the ADAR1+ADAR2 mediated guide variant.

[0050] [Figure 44A]The right barbell coordinates of an exemplary guide 610 targeting LRRK2 are shown. As shown in FIG. 44A, the coordinates of the right barbell were aligned between +22, +23, +24, +25, +26, +28, +30, +32, and +34 coordinates based on the A / C mismatch to determine the effect of each position on ADAR1 and ADAR1+ADAR2 editing. FIG. 44B shows the percent editing of an exemplary guide variant through ADAR1. FIG. 44C shows the percent editing of an exemplary guide variant through ADAR1+ADAR2. [Figure 44B] The right barbell coordinates of an exemplary guide 610 targeting LRRK2 are shown. As shown in FIG. 44A, the coordinates of the right barbell were aligned between +22, +23, +24, +25, +26, +28, +30, +32, and +34 coordinates based on the A / C mismatch to determine the effect of each position on ADAR1 and ADAR1+ADAR2 editing. FIG. 44B shows the percent editing of an exemplary guide variant through ADAR1. FIG. 44C shows the percent editing of an exemplary guide variant through ADAR1+ADAR2. [Figure 44C] The right barbell coordinates of an exemplary guide 610 targeting LRRK2 are shown. As shown in FIG. 44A, the coordinates of the right barbell were aligned between +22, +23, +24, +25, +26, +28, +30, +32, and +34 coordinates based on the A / C mismatch to determine the effect of each position on ADAR1 and ADAR1+ADAR2 editing. FIG. 44B shows the percent editing of an exemplary guide variant through ADAR1. FIG. 44C shows the percent editing of an exemplary guide variant through ADAR1+ADAR2.

[0051] [Figure 45A]The left barbell coordinates of an exemplary guide targeting LRRK2 are shown. As shown in Figure 45A, the left barbell coordinates are aligned between -10, -12, -14, -16, -18, -20, -22, and -24 coordinates based on A / C mismatch to determine the effect of each position on ADAR1 and ADAR1+ADAR2 editing. Figure 45B shows the percent editing of an exemplary guide variant via ADAR1. [Figure 45B] The left barbell coordinates of an exemplary guide targeting LRRK2 are shown. As shown in Figure 45A, the left barbell coordinates are aligned between -10, -12, -14, -16, -18, -20, -22, and -24 coordinates based on A / C mismatch to determine the effect of each position on ADAR1 and ADAR1+ADAR2 editing. Figure 45B shows the percent editing of an exemplary guide variant via ADAR1.

[0052] [Figure 46A] 1 shows the genetic manipulation of guide length for an exemplary guide targeting LRRK2, and the effect of guide length on ADAR1 and ADAR1+ADAR2 editing. [Figure 46B] Figure 1 shows the guide length engineering of an exemplary guide targeting LRRK2. Shows the percent editing of various length exemplary guide variants via ADAR1. The y-axis shows all engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0053] [Figure 47A] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-free guide RNA 2063 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 47B]Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-bearing guide RNA 2063 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0054] [Figure 48A] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-free guide RNA 1590 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 48B] Figure 1 shows the intracellular and cell-free editing of LRRK2 by an exemplary barbell-bearing guide RNA 1590 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0055] [Figure 49A] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-free guide RNA 2397 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 49B] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-bearing guide RNA 2397 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 49C]Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-bearing guide RNA 2397 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0056] [Figure 50A] 1 shows the genetic engineering of macro footprint positions of exemplary guide 2397 RNA variants. 2 shows a summary of RNA editing efficiency of exemplary guide 2397 RNA variants. [Figure 50B] Figure 1 shows the macro footprint position engineering of exemplary guide 2397 RNA variants. Shows the position-by-position editing efficiency of each exemplary guide RNA via ADAR1. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 50C] Figure 1 shows the macro footprint position engineering of exemplary guide 2397 RNA variants. Shows the editing efficiency of each exemplary guide RNA position via ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0057] [Figure 51A] 1 shows the genetic engineering of the right barbell coordinates of an exemplary guide 2397 RNA variant. 2 shows a summary of the RNA editing efficiency of an exemplary guide 2397 RNA variant. [Figure 51B] Figure 1 shows the right barbell coordinates of the genetic engineering of exemplary guide 2397 RNA variants. Shows the position-by-position editing efficiency of each exemplary guide RNA via ADAR1. The y-axis shows all the genetically engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 51C]Figure 1 shows the right barbell coordinates of the genetic engineering of the exemplary guide 2397 RNA variant. Figure 1 shows the editing efficiency of each exemplary guide RNA position via ADAR1+ADAR2. The y-axis shows all the genetically engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0058] [Figure 52] FIG. 13 shows the genetic manipulation of the left barbell coordinates of an exemplary guide 2397 RNA variant.

[0059] [Figure 53A] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-free guide RNA 1321 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 53B] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-bearing guide RNA1321 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0060] [Figure 54A] Figure 1 shows the intracellular and cell-free editing of LRRK2 by an exemplary barbell-free guide RNA 295 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 54B] Figure 1 shows the intracellular and cell-free editing of LRRK2 by an exemplary barbell-bearing guide RNA 295 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0061] [Figure 55A] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-free guide RNA 730 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 55B] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-bearing guide RNA 730 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0062] [Figure 56A] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-free guide RNA 708 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 56B] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-bearing guide RNA 708 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0063] [Figure 57A] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-free guide RNA 351 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 57B]Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-bearing guide RNA 351 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0064] [Figure 58A] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-free guide RNA 1326 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 58B] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-bearing guide RNA1326 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0065] [Figure 59A] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-free guide RNA 871 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 59B] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-bearing guide RNA 871 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 59C]Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-bearing guide RNA 871 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Fig. 59D] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-bearing guide RNA 871 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 59E] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-bearing guide RNA 871 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Fig. 59F] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-bearing guide RNA 871 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 59G] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-bearing guide RNA 871 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Fig. 59H] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-bearing guide RNA 871 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Fig. 59I]Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-bearing guide RNA 871 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Fig. 59J] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-bearing guide RNA 871 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 59K] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-bearing guide RNA 871 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 59L] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-bearing guide RNA 871 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 59M] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-bearing guide RNA 871 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 59N] Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-bearing guide RNA 871 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Fig. 59O]Figure 1 shows the intracellular and cell-free editing of LRRK2 by the exemplary barbell-bearing guide RNA 871 variant via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0066] [Figure 60A] 1 shows the genetic engineering of macro footprint positions of exemplary guide 871 RNA variants. 2 shows a summary of RNA editing efficiency of exemplary guide 871 RNA variants. [Figure 60B] Figure 1 shows the macro footprint position engineering of exemplary guide 871 RNA variants. Shows the editing efficiency of each exemplary guide RNA position via ADAR1. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 60C] Figure 1 shows the macro footprint position engineering of exemplary guide 871 RNA variants. Shows the editing efficiency of each exemplary guide RNA position via ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0067] [Figure 61A] 1 shows the genetic engineering of the right barbell coordinates of an exemplary guide 871 RNA variant. 2 shows a summary of the RNA editing efficiency of an exemplary guide 871 RNA variant. [Figure 61B] Figure 1 shows the right barbell coordinates of the genetic engineering of exemplary guide 871 RNA variants. Shows the position-by-position editing efficiency of each exemplary guide RNA via ADAR1. The y-axis shows all the genetically engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 61C]Figure 1 shows the right barbell coordinates of the genetic engineering of exemplary guide 871 RNA variants. Figure 1 shows the editing efficiency of each exemplary guide RNA position via ADAR1+ADAR2. The y-axis shows all the genetically engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0068] [Figure 62A] 1 shows the genetic engineering of the left barbell coordinates of an exemplary guide 871 RNA variant. 2 shows a summary of the RNA editing efficiency of an exemplary guide 871 RNA variant. [Figure 62B] Figure 1 shows the left barbell coordinates of the engineering of exemplary guide 871 RNA variants. Figure 1 shows the position-by-position editing efficiency of each exemplary guide RNA via ADAR1. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 62C] Figure 1 shows the left barbell coordinates of the engineering of exemplary guide 871 RNA variants. Figure 1 shows the editing efficiency of each exemplary guide RNA position via ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0069] [Figure 63A] 1 shows the genetic engineering of guide length for exemplary guide 871 RNA variants. 2 shows a summary of RNA editing efficiency for exemplary guide 871 RNA variants. [Figure 63B] Figure 1 shows the guide length of exemplary guide 871 RNA variants engineered. Figure 1 shows the editing efficiency of each exemplary guide RNA by position via ADAR1. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 63C]Figure 1 shows the guide length of exemplary guide 871 RNA variants engineered. Figure 2 shows the editing efficiency of each exemplary guide RNA position via ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0070] [Fig. 64A] 1 shows intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. 2 provides a summary of intracellular editing data of exemplary guide RNA 919 variants via ADAR1 and ADAR1+ADAR2. [Fig. 64B] Figure 1 shows the intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. The editing efficiency of each exemplary guide RNA 919 via ADAR1 and ADAR1+ADAR2 per position is shown. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Fig. 64C] Figure 1 shows the intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. The editing efficiency of each exemplary guide RNA 919 via ADAR1 and ADAR1+ADAR2 per position is shown. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Fig.64D] Figure 1 shows the intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. The editing efficiency of each exemplary guide RNA 919 via ADAR1 and ADAR1+ADAR2 per position is shown. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 64E]Figure 1 shows the intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. The editing efficiency of each exemplary guide RNA 919 via ADAR1 and ADAR1+ADAR2 per position is shown. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Fig.64F] Figure 1 shows the intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. The editing efficiency of each exemplary guide RNA 919 via ADAR1 and ADAR1+ADAR2 per position is shown. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 64G] Figure 1 shows the intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. The editing efficiency of each exemplary guide RNA 919 via ADAR1 and ADAR1+ADAR2 per position is shown. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Fig.64H] Figure 1 shows the intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. The editing efficiency of each exemplary guide RNA 919 via ADAR1 and ADAR1+ADAR2 per position is shown. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Fig.64I] Figure 1 shows the intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. The editing efficiency of each exemplary guide RNA 919 via ADAR1 and ADAR1+ADAR2 per position is shown. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Fig.64J]Figure 1 shows the intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. The editing efficiency of each exemplary guide RNA 919 via ADAR1 and ADAR1+ADAR2 per position is shown. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 64K] Figure 1 shows the intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. The editing efficiency of each exemplary guide RNA 919 via ADAR1 and ADAR1+ADAR2 per position is shown. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 64L] Figure 1 shows the intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. The editing efficiency of each exemplary guide RNA 919 via ADAR1 and ADAR1+ADAR2 per position is shown. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 64M] Figure 1 shows the intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. The editing efficiency of each exemplary guide RNA 919 via ADAR1 and ADAR1+ADAR2 per position is shown. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Fig. 64N] Figure 1 shows the intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. The editing efficiency of each exemplary guide RNA 919 via ADAR1 and ADAR1+ADAR2 per position is shown. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Fig.64O]Figure 1 shows the intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. The editing efficiency of each exemplary guide RNA 919 via ADAR1 and ADAR1+ADAR2 per position is shown. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 64P] Figure 1 shows the intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. The editing efficiency of each exemplary guide RNA 919 via ADAR1 and ADAR1+ADAR2 per position is shown. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 64Q] Figure 1 shows the intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. The editing efficiency of each exemplary guide RNA 919 via ADAR1 and ADAR1+ADAR2 per position is shown. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Fig.64R] Figure 1 shows the intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. The editing efficiency of each exemplary guide RNA 919 via ADAR1 and ADAR1+ADAR2 per position is shown. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Fig. 64S] Figure 1 shows the intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. The editing efficiency of each exemplary guide RNA 919 via ADAR1 and ADAR1+ADAR2 per position is shown. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 64T]Figure 1 shows the intracellular and cell-free editing of LRRK2 by exemplary guide RNA 919 variants. The editing efficiency of each exemplary guide RNA 919 via ADAR1 and ADAR1+ADAR2 per position is shown. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0071] [Figure 65A] 1 shows the genetic engineering of macro footprint positions of exemplary guide 919 RNA variants. 2 shows a summary of RNA editing efficiency of exemplary guide 919 RNA variants. [Figure 65B] Figure 1 shows the macro footprint position engineering of exemplary guide 919 RNA variants. Shows the editing efficiency of each exemplary guide RNA position via ADAR1. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 65C] Figure 1 shows the macro footprint position engineering of exemplary guide 919 RNA variants. Shows the editing efficiency of each exemplary guide RNA position via ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0072] [Figure 66A] 1 shows the genetic engineering of the right barbell coordinates of an exemplary guide 919 RNA variant. 2 shows a summary of the RNA editing efficiency of an exemplary guide 919 RNA variant. [Figure 66B] Figure 1 shows the right barbell coordinates of the genetic engineering of exemplary guide 919 RNA variants. Shows the position-by-position editing efficiency of each exemplary guide RNA via ADAR1. The y-axis shows all the genetically engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 66C]Figure 1 shows the right barbell coordinates of the genetic engineering of exemplary guide 919 RNA variants. Shows the editing efficiency of each exemplary guide RNA position via ADAR1+ADAR2. The y-axis shows all the genetically engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0073] [Figure 67A] 1 shows the genetic engineering of the left barbell coordinates of an exemplary guide 919 RNA variant. 2 shows a summary of the RNA editing efficiency of an exemplary guide 919 RNA variant. [Figure 67B] Figure 1 shows the left barbell coordinates of the genetic engineering of exemplary guide 919 RNA variants. Shows the position-by-position editing efficiency of each exemplary guide RNA via ADAR1. The y-axis shows all the genetically engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 67C] Figure 1 shows the left barbell coordinates of the genetic engineering of exemplary guide 919 RNA variants. Figure 1 shows the editing efficiency of each exemplary guide RNA position via ADAR1+ADAR2. The y-axis shows all the genetically engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0074] [Figure 68A] 1 shows the genetic engineering of guide length for exemplary guide 919 RNA variants. 2 shows a summary of RNA editing efficiency for exemplary guide 919 RNA variants. [Figure 68B] Figure 1 shows the guide length of exemplary guide 919 RNA variants engineered. Figure 1 shows the editing efficiency of each exemplary guide RNA by position via ADAR1. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 68C]Figure 1 shows the guide length of exemplary guide 919 RNA variants engineered. Figure 1 shows the editing efficiency of each exemplary guide RNA position via ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0075] [Figure 69A] Figure 1 shows the intracellular and cell-free editing of LRRK2 by exemplary guide RNA 844 variants via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 69B] Figure 1 shows the intracellular and cell-free editing of LRRK2 by exemplary guide RNA 844 variants via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 69C] Figure 1 shows the intracellular and cell-free editing of LRRK2 by exemplary guide RNA 844 variants via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0076] [Figure 70A] Figure 1 shows the intracellular and acellular editing of LRRK2 by exemplary guide RNA 1976 variants via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 70B]Figure 1 shows the intracellular and acellular editing of LRRK2 by exemplary guide RNA 1976 variants via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 70C] Figure 1 shows the intracellular and acellular editing of LRRK2 by exemplary guide RNA 1976 variants via ADAR1 and ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0077] [Figure 71A] 1 shows the genetic engineering of macro footprint positions of exemplary guide 1976 RNA variants. 2 shows a summary of RNA editing efficiency of exemplary guide 1976 RNA variants. [Figure 71B] Figure 1 shows the macro footprint position engineering of exemplary guide 1976 RNA variants. Shows the editing efficiency of each exemplary guide RNA position via ADAR1. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Figure 71C] Figure 1 shows the engineering of macro footprint positions of exemplary guide 1976 RNA variants. Shows the editing efficiency of each exemplary guide RNA position via ADAR1+ADAR2. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0078] [Figure 72A] 1 shows the genetic engineering of the right barbell coordinates of an exemplary guide 1976 RNA variant. 2 shows a summary of the RNA editing efficiency of an exemplary guide 1976 RNA variant. [Fig. 72B]Figure 1 shows the right barbell coordinates of the genetic engineering of exemplary guide 1976 RNA variants. Shows the position-by-position editing efficiency of each exemplary guide RNA via ADAR1. The y-axis shows all the genetically engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Fig. 72C] Figure 1 shows the right barbell coordinates of the genetic engineering of exemplary guide 1976 RNA variants. Shows the editing efficiency of each exemplary guide RNA position via ADAR1+ADAR2. The y-axis shows all the genetically engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0079] [Figure 73] 1 shows the genetic manipulation of the left barbell coordinates of an exemplary guide 1976 RNA variant.

[0080] [Figure 74] 1 shows the intracellular and cell-free editing of LRRK2 by an exemplary guide RNA 1700. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0081] [Fig. 75A] Figure 1 shows the intracellular and cell-free editing of LRRK2 by an exemplary guide RNA 860 variant. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Fig. 75B] Figure 1 shows the intracellular and cell-free editing of LRRK2 by an exemplary guide RNA 860 variant. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Fig. 75C]Figure 1 shows the intracellular and cell-free editing of LRRK2 by an exemplary guide RNA 860 variant. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Fig. 75D] Figure 1 shows the intracellular and cell-free editing of LRRK2 by an exemplary guide RNA 860 variant. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited. [Fig. 75E] Figure 1 shows the intracellular and cell-free editing of LRRK2 by an exemplary guide RNA 860 variant. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0082] [Figure 76] Figure 1 shows the intracellular and cell-free editing of LRRK2 by exemplary guide RNA 2108. The y-axis shows all the engineered guide RNA candidates tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0083] [Figure 77] 1 shows a comparison of editing efficiency between exemplary guide RNA variants targeting LRRK2.

[0084] [Figure 78] 1 shows a scAAV vector map for in vitro screening of the LRRK2 guide RNA variants generated herein when expressed in an AAV vector.

[0085] [Figure 79A] 1 shows the ADAR-mediated editing efficiency of an exemplary LRRK2 guide provided herein when transfected as a scAAV vector plasmid. [Fig. 79B]1 shows the ADAR-mediated editing efficiency of an exemplary LRRK2 guide provided herein when transduced as a scAAVDJ virus.

[0086] [Figure 80] Figure 1 shows a workflow for screening exemplary guide RNAs targeting LRRK2 in a broken GFP reporter system.

[0087] [Figure 81] FIG. 1 shows the editing efficiency of exemplary guides targeting LRRK2 via exogenous or endogenous ADARs in a broken GFP reporter system.

[0088] [Figure 82] 1 provides a comparison between linear and circularized versions of an exemplary guide RNA targeting LRRK2.

[0089] [Figure 83A] 1 shows the engineering of the length of the circularized LRRK2 guide RNA by increasing the length of the circularized guide RNA by an additional 15 and 30 nucleotides. [Figure 83B] 1 shows engineering the length of the circularized LRRK2 guide RNA by increasing the length of the circularized guide RNA by an additional 100 nucleotides.

[0090] [Figure 84] Figure 2 shows the effect of deleting selected uridines from an engineered circularized guide RNA targeting LRRK2 on editing of the target LRRK2 RNA.

[0091] [Fig. 85A] 1 shows in vivo editing of a target LRRK2 RNA by administration of an scAAV vector encoding an engineered guide RNA targeting LRRK2. 2 shows the in vivo editing efficiency of an scAAV vector encoding an engineered guide RNA targeting LRRK2 measured in the brain. [Fig. 85B] 1 shows in vivo editing of target LRRK2 RNA by administration of an scAAV vector encoding an engineered guide RNA targeting LRRK2. Quantification of engineered guide RNA expression in the brain relative to GAPDH control expression is shown. [Fig. 85C] 1 shows in vivo editing of target LRRK2 RNA by administration of an scAAV vector encoding an engineered guide RNA targeting LRRK2. 2 shows the in vivo editing efficiency of an scAAV vector encoding an engineered guide RNA targeting LRRK2 measured in the liver. [Fig. 85D] 1 shows in vivo editing of target LRRK2 RNA by administration of an scAAV vector encoding an engineered guide RNA targeting LRRK2. Quantification of engineered guide RNA expression in liver compared to GAPDH control expression is shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0092] RNA editing RNA editing can refer to the process that RNA can be enzymatically modified after synthesis with certain nucleosides. RNA editing can include any one of the following: insertion, deletion, or substitution of nucleotide(s). Examples of RNA editing include chemical modification, such as pseudouridylation (isomerization of uridine residues) and deamination (removal of amine groups from cytidine to generate uridine, or editing C to U or adenosine to inosine, or A to I). RNA editing can be used to introduce mutations, correct missense mutations, or edit coding or non-coding regions of RNA to inhibit RNA translation and cause protein knockdown.

[0093] Described herein are engineered guide RNAs that facilitate RNA editing of LRRK2 RNA by an RNA editing entity (e.g., adenosine deaminase acting on RNA (ADAR)) or a biologically active fragment thereof. The engineered guide RNAs described herein can include engineered guide RNAs having a polynucleotide sequence of any one of SEQ ID NO:2-SEQ ID NO:395 or SEQ ID NO:398-SEQ ID NO:472. In some examples, ADARs can be enzymes that catalyze the chemical conversion of adenosine to inosine in RNA. Inosine's properties are similar to those of guanosine (e.g., inosine forms two hydrogen bonds with cytosine), so inosine can be recognized as guanosine by the translation machinery of the cell. Thus, "adenosine to inosine (A→I) RNA editing" effectively changes the primary sequence of the RNA target.

[0094] Engineered guide RNA Disclosed herein are engineered guide RNAs (e.g., guide RNAs having any one of the polynucleotide sequences of SEQ ID NO:2 to SEQ ID NO:395 or SEQ ID NO:398 to SEQ ID NO:472) for site-specific selective editing of LRRK2 target RNA via an RNA editing entity or a biologically active fragment thereof, and engineered polynucleotides encoding the same. In some embodiments, the engineered guide RNAs of the present disclosure targeting LRRK2 include microfootprint sequences and / or macrofootprint sequences each including a potential structure, which is revealed when the engineered guide RNA hybridizes to the target RNA. The potential structure, when revealed, provides at least one structural feature selected from the group consisting of a bulge, an internal loop, a mismatch, a hairpin, and any combination thereof. In some embodiments, the engineered guide RNA of the present disclosure, upon hybridization of the engineered guide RNA to a sequence of a target RNA, forms a guide-target RNA scaffold that includes (i) a region that includes at least one structural feature and (ii) a macro footprint, such as a first internal loop (also referred to as "left bell" or "LB") and a second internal loop (also referred to as "right bell" or "RB") flanking opposing ends of the region of the guide-target RNA scaffold, where the engineered guide RNA promotes an increased amount of targeted editing of an adenosine of the target RNA via an adenosine deaminase enzyme RNA editing entity, compared to an otherwise equivalent engineered guide RNA that lacks the first and second internal loops. As described herein, the first and second internal loops may be described with reference to their position relative to an A / C mismatch of the target RNA scaffold, where the A of the A / C mismatch is the targeted adenosine of the LRRK2 target RNA. In some embodiments, the first internal loop is positioned about 7 bases away from the A / C mismatch to about 30 bases away from the A / C mismatch, with respect to the base of the first internal loop closest to the A / C mismatch.In some embodiments, the first internal loop is positioned 10 bases away from the A / C mismatch with respect to the base of the first internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned about 18 bases away from the A / C mismatch to about 34 bases away from the A / C mismatch with respect to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop is positioned 34 bases away from the A / C mismatch with respect to the base of the second internal loop closest to the A / C mismatch.

[0095] As described herein, a "microfootprint" sequence refers to a sequence having a potential structure, which, when revealed, promotes the editing of adenosines of a target RNA via adenosine deaminase enzyme. The macrofootprint may serve to guide an RNA editing entity (e.g., ADAR) and direct its activity to the microfootprint. In some embodiments, a nucleotide contained within the microfootprint sequence is positioned such that, when the guide RNA hybridizes to the target RNA, it faces the adenosine that is edited by adenosine deaminase and does not base pair with the adenosine that is edited. This nucleotide is referred to herein as a "mismatch position" or "mismatch" and may be a cytosine. The microfootprint sequence described herein has at least one structural feature selected from the group consisting of a bulge, an internal loop, a mismatch, a hairpin, and any combination thereof, upon hybridization of the engineered guide RNA to the target RNA. Engineered guide RNAs with superior microfootprint sequences can be selected based on their ability to promote editing of a specific target RNA (such as LRRK2 mRNA).

[0096] In some embodiments, the guide RNA of the present disclosure (e.g., a guide RNA having a polynucleotide sequence of any one of SEQ ID NO:2-SEQ ID NO:395 or SEQ ID NO:398-SEQ ID NO:472) may further comprise a macrofootprint. In some embodiments, the macrofootprint comprises a barbell macrofootprint. The microfootprint may serve to guide the RNA editing enzyme and direct its activity to the target adenosine to be edited. As described herein, "barbell" refers to a pair of internal loop potential structures that are revealed upon hybridization of the guide RNA to the target RNA. In some embodiments, each internal loop is located at the 5' or 3' end of the guide-target RNA scaffold formed upon hybridization of the guide RNA and the target RNA. In some embodiments, each internal loop is adjacent to the opposite side of the microfootprint sequence. By inserting barbell macrofootprint sequences adjacent to opposite sides of the microfootprint sequence, upon hybridization of the guide RNA to the LRRK2 target RNA, barbell internal loops are formed on opposite sides of the microfootprint, resulting in at least one structural feature that promotes editing of the LRRK2 target RNA.

[0097] Provided herein are engineered guide RNAs (such as potential guide RNAs comprising microfootprint sequences and / or macrofootprint sequences) and polynucleotides encoding the same; and compositions comprising the engineered guide RNAs or polynucleotides. As used herein, the term "engineered" with respect to a guide RNA or a polynucleotide encoding the same refers to a non-natural guide RNA or a polynucleotide encoding the same. For example, the disclosure provides engineered polynucleotides encoding engineered guide RNAs. In some embodiments, the engineered guide comprises RNA. In some embodiments, the engineered guide comprises DNA. In some examples, the engineered guide comprises modified RNA bases or unmodified RNA bases. In some embodiments, the engineered guide comprises modified DNA bases or unmodified DNA bases. In some examples, the engineered guide comprises both DNA and RNA bases.

[0098] In some examples, the engineered guides provided herein (e.g., a guide RNA having a polynucleotide sequence of any one of SEQ ID NO:2-SEQ ID NO:395 or SEQ ID NO:398-SEQ ID NO:472) include engineered guides that, upon hybridization to a target RNA molecule, can be configured to form, at least in part, a guide-target RNA scaffold with at least a portion of the LRRK2 target RNA molecule, where the guide-target RNA scaffold comprises at least one structural feature, and the guide-target RNA scaffold recruits an RNA editing entity and facilitates chemical modification of nucleotide bases of the LRRK2 target RNA molecule by the RNA editing entity.

[0099] In some examples, the LRRK2 target RNA of the engineered guide RNA of the present disclosure can be a pre-mRNA or an mRNA. In some embodiments, the engineered guide RNA of the present disclosure hybridizes to the sequence of the LRRK2 target RNA. In some embodiments, a portion of the engineered guide RNA (e.g., a targeting domain) hybridizes to the sequence of the LRRK2 target RNA. The portion of the engineered guide RNA that hybridizes to the target RNA is sufficiently complementary to the sequence of the target RNA for hybridization to occur.

[0100] A. Targeting Domains The engineered guide RNAs useful for facilitating editing of LRRK2 target RNA disclosed herein (e.g., guide RNAs having a polynucleotide sequence of any one of SEQ ID NO:2-SEQ ID NO:395 or SEQ ID NO:398-SEQ ID NO:472) can be engineered in any manner suitable for RNA editing. In some examples, the engineered guide RNAs typically include at least a targeting sequence that allows them to hybridize to a region of a target RNA molecule. The targeting sequence can also be referred to as a "targeting domain" or a "targeting region."

[0101] In some cases, the targeting domain of the engineered guide allows the engineered guide to target an RNA sequence by base pairing, e.g., Watson-Crick base pairing. In some examples, the targeting sequence may be present at either the N-terminus or C-terminus of the engineered guide. In some cases, the targeting sequence may be present at both termini. The targeting sequence may be of any length. In some cases, the targeting sequence may be at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 1, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 8 6, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 1 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, or up to about 200 nucleotides in length.In some cases, the targeting sequence is about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42 , 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 12 The length of the guide RNA may be up to 3, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, or 200 nucleotides. In some examples, the engineered guide RNA includes a targeting sequence that may be about 60 to about 500, about 60 to about 200, about 75 to about 100, about 80 to about 200, about 90 to about 120, or about 95 to about 115 nucleotides in length. In some examples, the engineered guide RNA includes a targeting sequence that may be about 100 nucleotides in length.

[0102] In some cases, the targeting domain comprises 95%, 96%, 97%, 98%, 99%, or 100% sequence complementarity to the target RNA. In some cases, the targeting sequence comprises less than 100% complementarity to the target RNA sequence. For example, the targeting sequence and the region of the target RNA that can be bound by the targeting sequence can have a single base mismatch.

[0103] B. Engineered guide RNAs with recruitment domains In some examples, the engineered guide RNA useful for promoting the editing of the LRRK2 target RNA described herein comprises a recruitment domain that recruits an RNA editing entity (e.g., ADAR), where in some examples, the recruitment domain is formed and exists in the absence of binding to the LRRK2 target RNA. The "recruitment domain" may also be referred to herein as a "recruitment sequence" or "recruitment region." In some examples, the engineered guide RNA may be configured to promote the editing of the nucleotide base of a polynucleotide of the LRRK2 target RNA region, the regulated expression of a polypeptide encoded by the LRRK2 target RNA, or both. In some cases, the engineered guide RNA may be configured to promote the editing of the nucleotide or polynucleotide base of the RNA region by an RNA editing entity. To promote editing, the engineered guide RNA of the present disclosure may be configured to recruit an RNA editing entity. Some embodiments provide an RNA editing entity comprising an ADAR protein, where the ADAR protein can be selected from the group consisting of ADAR1 (e.g., human or mouse), ADAR2 (e.g., human or mouse), and any combination thereof. Various RNA editing entity recruitment domains can be utilized. In some examples, the recruitment domain comprises glutamate ionotropic receptor AMPA type subunit 2 (GluR2) or Alu. In some embodiments of the present disclosure, the RNA editing entity can have an ADAR protein. The ADAR protein can be selected from the group consisting of ADAR1, ADAR2, and a combination of ADAR1 and ADAR2. Other embodiments can be directed to an RNA editing entity selected from the group consisting of human ADAR1, mouse ADAR1, human ADAR2, mouse ADAR2, and any combination thereof.

[0104] In some examples, multiple recruitment domains can be included in the engineered guide RNA of the present disclosure. In examples where a recruitment domain can be present, the recruitment domain can be utilized to position the RNA editing entity to effectively react with the target RNA after the targeting sequence, for example, the antisense sequence, is hybridized to the target RNA. In some cases, the recruitment domain can allow the RNA editing entity to bind transiently to the engineered guide RNA. In some examples, the recruitment domain can allow the RNA editing entity to bind persistently to the engineered guide RNA. The recruitment domain can be of any length. In some cases, the recruitment domain can be about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75 up to about 80 nucleotides in length. In some cases, the recruitment domain can be about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, or 80 nucleotides in length or less. In some cases, the recruitment domain may be about 45 nucleotides in length. In some cases, at least a portion of the recruitment domain comprises at least 1 to about 75 nucleotides. In some cases, at least a portion of the recruitment domain comprises about 45 nucleotides to about 60 nucleotides.

[0105] In some embodiments, the recruitment domain comprises a GluR2 sequence or a functional fragment thereof. In some cases, the GluR2 sequence can be recognized by an RNA editing entity, such as an ADAR or a biologically active fragment thereof. In some embodiments, the GluR2 sequence can be a non-natural sequence. In some cases, the GluR2 sequence can be modified, for example, for enhanced recruitment. In some embodiments, the GluR2 sequence can include a portion of a naturally occurring GluR2 sequence and a synthetic sequence.

[0106] In some examples, the recruitment domain comprises a sequence having at least about 70%, 80%, 85%, 90%, 95%, 98%, 99%, or 100% identity and / or length to the GluR2 sequence, or GUGGAAUAGUAUAACAAUAUGCUAAAUGUUGUUAUAGUAUCCCAC (SEQ ID NO: 1). In some cases, the recruitment domain may comprise at least about 80% sequence homology to at least about 10, 15, 20, 25, or 30 nucleotides of SEQ ID NO: 1. In some examples, the recruitment domain may comprise at least about 90%, 95%, 96%, 97%, 98%, or 99% sequence homology and / or length to SEQ ID NO: 1.

[0107] Any number of recruitment domains may be found in the engineered RNA of the present disclosure. In some instances, at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, or up to about 10 recruitment domains may be included in the engineered RNA. The recruitment domain may be present at any position in the engineered guide RNA. In some cases, the recruitment domain may be at the N-terminus, middle, or C-terminus of the polynucleotide. The recruitment domain may be present upstream or downstream of the targeting sequence. In some cases, the recruitment domain is adjacent to the targeting sequence of the guide. The recruitment sequence may include all ribonucleotides or deoxyribonucleotides, although in some cases recruitment domains that include both ribonucleotides and deoxyribonucleotides may not be excluded.

[0108] C. Engineered guide RNAs containing microfootprint sequences with potential structures In some examples, the engineered guides disclosed herein useful for facilitating editing of LRRK2 target RNA via an RNA editing entity (e.g., guide RNAs having any one of the polynucleotide sequences of SEQ ID NO:2-SEQ ID NO:395 or SEQ ID NO:398-SEQ ID NO:472) can be engineered potential guide RNAs. "Engineered potential guide RNA" refers to an engineered guide RNA that includes a potential structure. The microfootprint sequence of a guide RNA that includes a potential structure (e.g., a "potential structure guide RNA") can include a sequence portion that, upon hybridization to a target RNA, forms at least a portion of a structural feature other than a single A / C mismatch feature at the target adenosine to be edited. "Potential structure" refers to a structural feature that is substantially formed upon hybridization of the guide RNA to the target RNA. For example, the sequence of the guide RNA provides one or more structural features, but these structural features are substantially formed only upon hybridization to the target RNA, and thus the one or more potential structural features appear as structural features upon hybridization to the target RNA. Upon hybridization of the guide RNA to the target RNA, structural features are formed, thus revealing the potential structure imparted to the guide RNA.

[0109] A double-stranded RNA (dsRNA) substrate is formed upon hybridization of the engineered guide RNA of the present disclosure to a target RNA. The resulting dsRNA substrate is also referred to herein as a "guide-target RNA scaffold."

[0110] In some embodiments, the present disclosure provides engineered guide RNAs that include a barbell macrofootprint. In some embodiments, the present disclosure provides engineered guide RNAs that include a microfootprint. In some embodiments, the present disclosure provides engineered guide RNAs that include a macrofootprint and a microfootprint, where the macrofootprint includes a barbell (or internal loop) near the 5' and 3' ends of the guide-target RNA scaffold, and the microfootprint includes other structural features including, but not limited to, a mismatch, a symmetric internal loop, an asymmetric internal loop, a symmetric bulge, or an asymmetric bulge. For example, the engineered guide RNAs disclosed herein may have a macrofootprint and a microfootprint of an A / G mismatch at a local off-target adenosine. The engineered guide RNAs disclosed herein may have a macrofootprint and a microfootprint of a 1 / 0 asymmetric bulge (formed by an A in the target RNA and a U deletion in the engineered guide RNA) at a local off-target adenosine. The engineered guide RNAs disclosed herein may have a barbell macro footprint (including an internal loop near the 5' end of the guide-target RNA scaffold and an internal loop near the 3' end of the guide-target RNA scaffold) and a micro footprint of an A / G mismatch at a local off-target adenosine. The engineered guide RNAs disclosed herein may have a barbell macro footprint (including an internal loop near the 5' end of the guide-target RNA scaffold and an internal loop near the 3' end of the guide-target RNA scaffold) and a micro footprint of a 1 / 0 asymmetric bulge (formed by an A in the target RNA and a U deletion in the engineered guide RNA) at a local off-target adenosine.In some embodiments, the engineered guide RNAs disclosed herein may have a barbell macrofootprint (including an internal loop near the 5' end of the guide-target RNA scaffold and an internal loop near the 3' end of the guide-target RNA scaffold) and a microfootprint of a 5 / 5 symmetric loop, a 1 / 1 G / G mismatch, and a 3 / 3 symmetric bulge that enhances on-target adenosine editing while also reducing local off-target adenosine editing. In some embodiments, the barbell macrofootprint is engineered to form an internal loop at position -14 and an internal loop at position +22 relative to the target adenosine (position 0). In some embodiments, the barbell macrofootprint is engineered to form an internal loop at position -20 and an internal loop at position +26 relative to the target adenosine (position 0).

[0111] Figure 1 shows a legend of various exemplary structural features present in the guide-target RNA scaffold formed upon hybridization of a potential guide RNA of the present disclosure to a target RNA. Exemplary structural features shown include an 8 / 7 asymmetric loop (8 nucleotides on the target RNA side and 7 nucleotides on the guide RNA side), a 2 / 2 symmetric bulge (2 nucleotides on the target RNA side and 2 nucleotides on the guide RNA side), a 1 / 1 mismatch (1 nucleotide on the target RNA side and 1 nucleotide on the guide RNA side), a 5 / 5 symmetric internal loop (5 nucleotides on the target RNA side and 5 nucleotides on the guide RNA side), a 24bp region (24 nucleotides on the target RNA side base-paired with 24 nucleotides on the guide RNA side), and a 2 / 3 asymmetric bulge (2 nucleotides on the target RNA side and 3 nucleotides on the guide RNA side). Unless otherwise noted, the number of nucleotides involved in a given structural feature is shown as nucleotides on the guide RNA side versus nucleotides on the target RNA side. This legend also shows the positional annotation cues in each figure. For example, the target nucleotide to be edited is represented as position 0. Each nucleotide downstream (3') of the target nucleotide to be edited is counted by +1. Each nucleotide upstream (5') of the target nucleotide to be edited is counted by -1. Thus, an exemplary 2 / 2 symmetric bulge in this legend is at position +12 to +13 of the guide-target RNA scaffold. Similarly, a 2 / 3 asymmetric bulge in this legend is at position -36 to -37 of the guide-target RNA scaffold. As used herein, positional annotations are provided relative to the target nucleotide to be edited and on the target RNA side of the guide-target RNA scaffold. As used herein, when a single position is annotated, the structural feature extends from that position away from position 0 (the target nucleotide to be edited). For example, when a potential guide RNA is annotated herein as forming a 2 / 3 asymmetric bulge at position -36, the 2 / 3 asymmetric bulge is formed at position -36 to -37 relative to the target nucleotide to be edited (position 0) on the target RNA side of the guide-target RNA scaffold.As another example, if a potential guide RNA is annotated herein as forming a 2 / 2 symmetric bulge at position +12, then the 2 / 2 symmetric bulge forms at positions +12 to +13 relative to the edited target nucleotide (position 0) on the target RNA side of the guide-target RNA scaffold.

[0112] In some examples, the engineered potential guide RNA lacks a recruitment domain, and recruitment of the RNA editing entity can be achieved by structural features of the guide-target RNA scaffold formed by hybridization of the engineered guide RNA with the target RNA. In some examples, the engineered guide does not contain structural features that recruit the RNA editing entity (e.g., ADAR) when present in aqueous solution and not bound to the target RNA molecule. Upon hybridization to the target RNA, the engineered potential guide RNA forms with the target RNA molecule one or more structural features present in the guide-target RNA scaffold that recruit the RNA editing entity (e.g., ADAR).

[0113] Structural features that may be present in the guide-target RNA scaffold of the present disclosure are described herein. Examples of features include mismatches, bulges (symmetric or asymmetric), internal loops (symmetric or asymmetric internal loops), or hairpins (mobilizing or non-mobilizing hairpins). The engineered guide RNA of the present disclosure may have 1-50 features. The engineered guide RNA of the present disclosure may have 1-5, 5-10, 10-15, 15-20, 20-25, 25-30, 30-35, 35-40, 40-45, 45-50, 5-20, 1-3, 4-5, 2-10, 20-40, 10-40, 20-50, 30-50, 4-7, or 8-10 features. In some embodiments, structural features (e.g., mismatches, bulges, internal loops) may be formed from latent structures of the engineered potential guide RNA upon hybridization of the engineered potential guide RNA to the target RNA, thus forming the guide-target RNA scaffold. In some embodiments, structural features are not formed from latent structures, but instead are preformed structures (e.g., GluR2 recruitment hairpins or hairpins derived from U7 snRNA).

[0114] A guide-target RNA scaffold is formed upon hybridization of the engineered guide RNA of the present disclosure to the target RNA. As disclosed herein, a mismatch refers to a single nucleotide in the guide RNA that is not paired with an opposing single nucleotide in the target RNA in the guide-target RNA scaffold. A mismatch can include any two single nucleotides that do not base pair. If the number of involved nucleotides on the guide RNA side and the target RNA side is more than one, the resulting structure is no longer considered a mismatch, but rather a bulge or internal loop, depending on the size of the structural feature. In some embodiments, the mismatch is an A / C mismatch. An A / C mismatch can include a C of the engineered guide RNA of the present disclosure facing an A of the target RNA. An A / C mismatch can include an A of the engineered guide RNA of the present disclosure facing a C of the target RNA. A G / G mismatch can include a G of the engineered guide RNA of the present disclosure facing a G of the target RNA.

[0115] In some embodiments, mismatches located 5' of the editing site can facilitate base flipping of the edited target A. Mismatches can also help confer sequence specificity. Thus, mismatches can be structural features formed from potential structures provided by engineered potential guide RNAs.

[0116] In another embodiment, the structural feature comprises a wobble base. A wobble base pair refers to two bases that weakly base pair. For example, the wobble base pair of the present disclosure can refer to G paired with U. Thus, a wobble base pair can be a structural feature formed from the potential structure that is provided by the potential guide RNA that is engineered.

[0117] In some cases, the structural feature may be a hairpin. As disclosed herein, a hairpin comprises an RNA duplex in which a portion of a single stranded RNA folds back on itself to form an RNA duplex. The portions of the single stranded RNA fold back due to having nucleotide sequences that base pair with each other, separated by an intervening sequence that does not base pair with itself, thereby forming a base-paired portion and an intervening loop portion that does not base pair. The hairpin may have a length of 10-500 nucleotides across the duplex structure. The loop portion of the hairpin may be 3-15 nucleotides long. The hairpin may be present in any of the engineered guide RNAs disclosed herein. The engineered guide RNAs disclosed herein may have 1-10 hairpins. In some embodiments, the engineered guide RNAs disclosed herein have one hairpin. In some embodiments, the engineered guide RNAs disclosed herein have two hairpins. As disclosed herein, hairpins may include recruitment hairpins or non-recruitment hairpins.Hairpins may be present anywhere within the engineered guide RNA of the present disclosure.In some embodiments, one or more hairpins may be present at or near the 3' end of the engineered guide RNA of the present disclosure, at or near the 5' end of the engineered guide RNA of the present disclosure, at or near the targeting domain of the engineered guide RNA of the present disclosure, or any combination thereof.

[0118] In some aspects, the structural feature comprises a non-recruiting hairpin. As disclosed herein, the non-recruiting hairpin does not have the primary function of recruiting an RNA editing entity. In some examples, the non-recruiting hairpin does not recruit an RNA editing entity. In some examples, the non-recruiting hairpin has a dissociation constant for binding to an RNA editing entity under physiological conditions that are insufficient for binding. For example, the non-recruiting hairpin has a binding dissociation constant for an RNA editing entity at 25°C that is greater than about 1 mM, 10 mM, 100 mM, or 1 M, as measured in an in vitro assay. The non-recruiting hairpin may exhibit the function of improving the localization of an engineered guide RNA to a target RNA. In some embodiments, the non-recruiting hairpin improves intranuclear tethering. In some embodiments, the non-recruiting hairpin comprises a hairpin derived from U7 snRNA. Thus, non-recruiting hairpins, such as those derived from U7 snRNA, are preformed structural features that may be present in constructs that include engineered guide RNA constructs, and are not formed by potential structures provided in engineered potential guide RNAs.

[0119] Hairpins of the present disclosure can be of any length, hi some embodiments, hairpins can be from about 10 to 500 nucleotides or more. In some cases, the hairpin may be about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 1 46, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202, 203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217, 218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232, 233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247, 248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262, 263,264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277, 278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292, 293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 3 24, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337, 338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352, 353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367, 368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, ​​383, 384 , 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486 45, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500 nucleotides, or more. In other cases, the hairpins are 10-20, 10-30, 10-40,10~50, 10~60, 10~70, 10~80, 10~90, 10~100, 10~110, 10~120, 10~130, 10~140, 10~150, 10~160, 10~170, 10~180, 10~190, 10~200, 10~210, 10~220, 10~230, 10~240, 10~250, 10~260, 10~270, 10~280, 10~ It may contain 290, 10 to 300, 10 to 310, 10 to 320, 10 to 330, 10 to 340, 10 to 350, 10 to 360, 10 to 370, 10 to 380, 10 to 390, 10 to 400, 10 to 410, 10 to 420, 10 to 430, 10 to 440, 10 to 450, 10 to 460, 10 to 470, 10 to 480, 10 to 490, or 10 to 500 nucleotides.

[0120] The guide-target RNA scaffold is formed upon hybridization of the engineered guide RNA of the present disclosure to the target RNA. As disclosed herein, a bulge refers to a structure that is formed substantially only upon formation of the guide-target RNA scaffold, in which consecutive nucleotides of either the engineered guide RNA or the target RNA are not complementary to their corresponding positions in the opposing strand. The bulge may alter the secondary or tertiary structure of the guide-target RNA scaffold. The bulge may independently have 0-4 consecutive nucleotides on the guide RNA side of the guide-target RNA scaffold and 1-4 consecutive nucleotides on the target RNA side of the guide-target RNA scaffold, or the bulge may independently have 0-4 nucleotides on the target RNA side of the guide-target RNA scaffold and 1-4 consecutive nucleotides on the guide RNA side of the guide-target RNA scaffold. However, as used herein, bulge does not refer to a structure in which the single nucleotide involved in the engineered guide RNA and the single nucleotide involved in the target RNA do not base-pair, and the single nucleotide involved in the engineered guide RNA and the single nucleotide involved in the target RNA that do not base-pair are referred to as mismatches herein. Furthermore, if the number of involved nucleotides on either the guide RNA side or the target RNA side exceeds four, the resulting structure is no longer considered a bulge, but rather an internal loop. In some embodiments, the guide-target RNA scaffold of the present disclosure has two bulges. In some embodiments, the guide-target RNA scaffold of the present disclosure has three bulges. In some embodiments, the guide-target RNA scaffold of the present disclosure has four bulges. Thus, a bulge can be a structural feature formed from a potential structure provided by a potential engineered guide RNA.

[0121] In some embodiments, the presence of a bulge in the guide-target RNA scaffold may position or help position the ADAR to selectively edit the target A in the target RNA and reduce off-target editing of non-target A(s) in the target RNA. In some embodiments, the presence of a bulge in the guide-target RNA scaffold may recruit or help recruit additional amounts of ADAR. The bulge in the guide-target RNA scaffold disclosed herein may recruit other proteins, such as other RNA editing entities. In some embodiments, the bulge located 5' of the editing site may facilitate base flipping of the target A to be edited. The bulge may also help to impart sequence specificity to the A of the target RNA to be edited compared to other A(s) present in the target RNA. For example, the bulge may help to direct ADAR editing by constraining it to an orientation that results in selective editing of the target A.

[0122] The guide-target RNA scaffold is formed upon hybridization of the engineered guide RNA of the present disclosure to the target RNA. The bulge can be a symmetric bulge or an asymmetric bulge. A symmetric bulge is formed when the same number of nucleotides are present in both bulges. For example, a symmetric bulge of a guide-target RNA scaffold of the present disclosure can have the same number of nucleotides on the engineered guide RNA side and the target RNA side of the guide-target RNA scaffold. A symmetric bulge of the present disclosure can be formed by 2 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 2 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric bulge of the present disclosure can be formed by 3 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 3 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric bulge of the present disclosure can be formed by 4 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 4 nucleotides on the target RNA side of the guide-target RNA scaffold. Thus, the symmetric bulge may be a structural feature formed from the potential structures provided by the engineered potential guide RNA.

[0123] The guide-target RNA scaffold is formed upon hybridization of the engineered guide RNA of the present disclosure to the target RNA. The bulge can be a symmetric bulge or an asymmetric bulge. An asymmetric bulge is formed when a different number of nucleotides are present on either side of the bulge. For example, the asymmetric bulge of the guide-target RNA scaffold of the present disclosure can have a different number of nucleotides on the engineered guide RNA side and the target RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure can be formed by 0 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and 1 nucleotide on the target RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure can be formed by 0 nucleotides on the target RNA side of the guide-target RNA scaffold and 1 nucleotide on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure can be formed by 0 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and 2 nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by 0 nucleotides on the target RNA side of the guide-target RNA scaffold and 2 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by 0 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and 3 nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by 0 nucleotides on the target RNA side of the guide-target RNA scaffold and 3 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by 0 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and 4 nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by 0 nucleotides on the target RNA side of the guide-target RNA scaffold and 4 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure can be formed by one nucleotide on the engineered guide RNA side of the guide-target RNA scaffold and two nucleotides on the target RNA side of the guide-target RNA scaffold.The asymmetric bulge of the present disclosure may be formed by one nucleotide on the target RNA side of the guide-target RNA scaffold and two nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by one nucleotide on the engineered guide RNA side of the guide-target RNA scaffold and three nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by one nucleotide on the target RNA side of the guide-target RNA scaffold and three nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by one nucleotide on the engineered guide RNA side of the guide-target RNA scaffold and four nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by one nucleotide on the target RNA side of the guide-target RNA scaffold and four nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by two nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and three nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by 2 nucleotides on the target RNA side of the guide-target RNA scaffold and 3 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by 2 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and 4 nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by 2 nucleotides on the target RNA side of the guide-target RNA scaffold and 4 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by 3 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and 4 nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric bulge of the present disclosure may be formed by 3 nucleotides on the target RNA side of the guide-target RNA scaffold and 4 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold.Thus, the asymmetric bulge may be a structural feature formed from the potential structures provided by the engineered potential guide RNA.

[0124] In some cases, the structural feature may be an internal loop. As disclosed herein, an internal loop refers to a structure that is formed substantially only upon the formation of a guide-target RNA scaffold, in which the nucleotides of either the engineered guide RNA or the target RNA are not complementary to their corresponding positions in the opposite strand, and one side of the internal loop on either the target RNA side or the engineered guide RNA side of the guide-target RNA scaffold has 5 nucleotides or more. If the number of nucleotides involved on both the guide RNA side and the target RNA side is reduced to less than 5, the resulting structure is no longer considered an internal loop, but rather a bulge or mismatch, depending on the size of the structural feature. The internal loop may be a symmetric internal loop or an asymmetric internal loop. An internal loop present near the editing site may be useful for base flipping of the target A of the target RNA to be edited.

[0125] One side of the internal loop on either the target RNA side or the engineered guide RNA side of the guide-target RNA scaffold can be formed by 5 to 150 nucleotides. One side of the internal loop can be formed by 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 120, 135, 140, 145, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800, 900, or 1000 nucleotides, or any number of nucleotides in between. One side of the internal loop may be formed by 5 nucleotides. One side of the internal loop may be formed by 10 nucleotides. One side of the internal loop may be formed by 15 nucleotides. One side of the internal loop may be formed by 20 nucleotides. One side of the internal loop may be formed by 25 nucleotides. One side of the internal loop may be formed by 30 nucleotides. One side of the internal loop may be formed by 35 nucleotides. One side of the internal loop may be formed by 40 nucleotides. One side of the internal loop may be formed by 45 nucleotides. One side of the internal loop may be formed by 50 nucleotides. One side of the internal loop may be formed by 55 nucleotides. One side of the internal loop may be formed by 60 nucleotides. One side of the internal loop may be formed by 65 nucleotides. One side of the internal loop may be formed by 70 nucleotides. One side of the internal loop may be formed by 75 nucleotides. One side of the internal loop may be formed by 80 nucleotides. One side of the internal loop may be formed by 85 nucleotides. One side of the internal loop may be formed by 90 nucleotides. One side of the internal loop may be formed by 95 nucleotides. One side of the internal loop may be formed by 100 nucleotides. One side of the internal loop may be formed by 110 nucleotides. One side of the internal loop may be formed by 120 nucleotides. One side of the internal loop may be formed by 130 nucleotides. One side of the internal loop may be formed by 140 nucleotides.One side of the internal loop may be formed by 150 nucleotides. One side of the internal loop may be formed by 200 nucleotides. One side of the internal loop may be formed by 250 nucleotides. One side of the internal loop may be formed by 300 nucleotides. One side of the internal loop may be formed by 350 nucleotides. One side of the internal loop may be formed by 400 nucleotides. One side of the internal loop may be formed by 450 nucleotides. One side of the internal loop may be formed by 500 nucleotides. One side of the internal loop may be formed by 600 nucleotides. One side of the internal loop may be formed by 700 nucleotides. One side of the internal loop may be formed by 800 nucleotides. One side of the internal loop may be formed by 900 nucleotides. One side of the internal loop may be formed by 1000 nucleotides. Thus, the internal loop may be a structural feature formed from a potential structure provided by an engineered potential guide RNA.

[0126] The internal loop may be a symmetric internal loop or an asymmetric internal loop. A symmetric internal loop is formed when the same number of nucleotides are present on both sides of the internal loop. For example, a symmetric internal loop of the guide-target RNA scaffold of the present disclosure may have the same number of nucleotides on the engineered guide RNA side and the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 5 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 6 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 6 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 7 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 7 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 8 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 8 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 9 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 9 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 10 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 10 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 15 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 15 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 20 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 20 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 30 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 30 nucleotides on the target RNA side of the guide-target RNA scaffold.A symmetric internal loop of the present disclosure may be formed by 40 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 40 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 50 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 50 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 60 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 60 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 70 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 70 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 80 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 80 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 90 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 90 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 100 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 100 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 110 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 110 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 120 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 120 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 130 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 130 nucleotides on the target RNA side of the guide-target RNA scaffold.A symmetric internal loop of the present disclosure may be formed by 140 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 140 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 150 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 150 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 200 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 200 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 250 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 250 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 300 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 300 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 350 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 350 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 400 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 400 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 450 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 450 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 500 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 500 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 600 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 600 nucleotides on the target RNA side of the guide-target RNA scaffold.The symmetric internal loop of the present disclosure may be formed by 700 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 700 nucleotides on the target RNA side of the guide-target RNA scaffold. The symmetric internal loop of the present disclosure may be formed by 800 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 800 nucleotides on the target RNA side of the guide-target RNA scaffold. The symmetric internal loop of the present disclosure may be formed by 900 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 900 nucleotides on the target RNA side of the guide-target RNA scaffold. The symmetric internal loop of the present disclosure may be formed by 1000 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 1000 nucleotides on the target RNA side of the guide-target RNA scaffold. Thus, the symmetric internal loop may be a structural feature formed from a potential structure provided by a potential engineered guide RNA.

[0127] Asymmetric internal loops are formed when there are different numbers of nucleotides on either side of the internal loop. For example, an asymmetric internal loop in a guide-target RNA scaffold of the present disclosure can have a different number of nucleotides on the engineered guide RNA side and the target RNA side of the guide-target RNA scaffold.

[0128] The asymmetric internal loop of the present disclosure may be formed by 5-150 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and 5-150 nucleotides on the target RNA side of the guide-target RNA scaffold, where the number of nucleotides on the engineered side of the guide-target RNA scaffold target is different from the number of nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5-1000 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and 5-1000 nucleotides on the target RNA side of the guide-target RNA scaffold, where the number of nucleotides on the engineered side of the guide-target RNA scaffold target is different from the number of nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and 6 nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 6 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and 7 nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 7 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and an 8 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 8 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and a 9 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 9 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and a 10 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and a 10 nucleotide internal loop on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 6 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and a 7 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 6 nucleotides on the target RNA side of the guide-target RNA scaffold and a 7 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 6 nucleotide on the engineered guide RNA side of the guide-target RNA scaffold and an 8 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 6 nucleotide on the target RNA side of the guide-target RNA scaffold and an 8 nucleotide on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 6 nucleotide on the engineered guide RNA side of the guide-target RNA scaffold and a 9 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 6 nucleotide on the target RNA side of the guide-target RNA scaffold and a 9 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 6 nucleotide on the engineered guide RNA side of the guide-target RNA scaffold and a 10 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 6 nucleotides on the target RNA side of the guide-target RNA scaffold and 10 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure may be formed by a 7 nucleotide on the engineered guide RNA side of the guide-target RNA scaffold and an 8 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 7 nucleotide on the target RNA side of the guide-target RNA scaffold and an 8 nucleotide on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 7 nucleotide on the engineered guide RNA side of the guide-target RNA scaffold and a 9 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 7 nucleotide on the target RNA side of the guide-target RNA scaffold and a 9 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 7 nucleotide on the engineered guide RNA side of the guide-target RNA scaffold and a 10 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 7 nucleotides on the target RNA side of the guide-target RNA scaffold and 10 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 8 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and a 9 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 8 nucleotides on the target RNA side of the guide-target RNA scaffold and 9 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 8 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and a 10 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 8 nucleotides on the target RNA side of the guide-target RNA scaffold and 10 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure may be formed by a 9 nucleotide internal loop on the engineered guide RNA side of the guide-target RNA scaffold and a 10 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 9 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold and a 10 nucleotide internal loop on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 5 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold and a 50 nucleotide internal loop on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 5 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold and a 100 nucleotide internal loop on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 5 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold and a 150 nucleotide internal loop on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure may be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 150 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure may be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 150 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure may be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure may be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 150 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 150 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 150 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure may be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure may be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. Thus, the asymmetric internal loop may be a structural feature formed from a potential structure provided by a potential engineered guide RNA.

[0129] As disclosed herein, a "base-paired (bp) region" refers to a region of a guide-target RNA scaffold where a base of the guide RNA is paired with an opposing base of the target RNA. A base-paired region can extend from at or near one end of the guide-target RNA scaffold to at or near the other end of the guide-target RNA scaffold. A base-paired region can extend between two structural features. A base-paired region can extend from at or near one end of the guide-target RNA scaffold to at or near a structural feature. A base-paired region can extend from a structural feature to at or near the other end of the guide-target RNA scaffold. In some embodiments, the base-paired region is between 1 bp and 100 bp, between 1 bp and 90 bp, between 1 bp and 80 bp, between 1 bp and 70 bp, between 1 bp and 60 bp, between 1 bp and 50 bp, between 1 bp and 45 bp, between 1 bp and 40 bp, between 1 bp and 35 bp, between 1 bp and 30 bp, between 1 bp and 25 bp, between 1 bp and 20 bp, between 1 bp and 15 bp, between 1 bp and 10 bp, between 1 bp and 5 bp, between 5 bp and 10 bp, between 5 bp and 20 bp, between 10 bp and 20 bp, between 10 bp and 50 bp, between 5 bp and 50 bp, at least 1 bp, at least 2 bp, at least 3 bp , at least 4 bp, at least 5 bp, at least 6 bp, at least 7 bp, at least 8 bp, at least 9 bp, at least 10 bp, at least 12 bp, at least 14 bp, at least 16 bp, at least 18 bp, at least 20 bp, at least 25 bp, at least 30 bp, at least 35 bp, at least 40 bp, at least 45 bp, at least 50 bp, at least 60 bp, at least 70 bp, at least 80 bp, at least 90 bp, at least 100 bp.

[0130] Barbell Macro Footprint In some embodiments, the engineered guide RNA targeting LRRK2 may include a macro footprint sequence, such as a barbell macro footprint. As disclosed herein, the barbell macro footprint sequence generates a pair of internal loop structural features upon hybridization to the target RNA, which improves one or more aspects of editing compared to an otherwise equivalent guide RNA that lacks the pair of internal loop structural features. In some examples, the inclusion of the barbell macro footprint sequence improves the amount of editing of the adenosine of interest (e.g., on-target adenosine) compared to the amount of editing of the on-target adenosine in an equivalent guide RNA that lacks the barbell macro footprint sequence. In some examples, the inclusion of the barbell macro footprint sequence reduces the amount of editing of adenosines other than the adenosine of interest (e.g., reduces off-target adenosines) compared to the amount of off-target adenosines in an equivalent guide RNA that lacks the barbell macro footprint sequence.

[0131] The macro footprint sequence may be positioned adjacent to the micro footprint sequence. Additionally, the macro footprint sequence may be adjacent to the micro footprint sequence, but may also incorporate additional potential structures adjacent to either end of the macro footprint. In some embodiments, such additional potential structures are included as part of the macro footprint. In some embodiments, such additional potential structures are separate from the macro footprint, distinct, or both.

[0132] In some embodiments, the macro footprint sequence comprises a barbell macro footprint sequence that includes a potential structure that, when manifested, produces a first internal loop and a second internal loop.

[0133] In some examples, the first internal loop is located "near the 5' end of the guide-target RNA scaffold" and the second internal loop is located near the 3' end of the guide-target RNA scaffold. The length of the dsRNA includes the 5' end and the 3' end, and up to half the length of the guide-target RNA scaffold on the 5' end side can be considered "near the 5' end", and up to half the length of the guide-target RNA scaffold on the 3' end side can be considered "near the 3' end". Non-limiting examples of the 5' end can include about 50% or less, about 45%, about 40%, about 35%, about 30%, about 25%, about 20%, about 15%, about 10%, or about 5% of the total length of the dsRNA on the 5' end side. Non-limiting examples of the 3' end include about 50% or less, about 45%, about 40%, about 35%, about 30%, about 25%, about 20%, about 15%, about 10%, or about 5% of the total length of the dsRNA on the 3' end.

[0134] The engineered guide RNAs of the present disclosure that include a barbell macro footprint sequence (appearing as a first internal loop and a second internal loop) can improve the RNA editing efficiency of the LRRK2 target RNA, generally increasing the amount or percentage of RNA editing and also improving on-target nucleotide editing, such as on-target adenosine. In some embodiments, the engineered guide RNAs of the present disclosure that include a first internal loop and a second internal loop can also promote a reduction in the amount of off-target nucleotide editing, such as off-target adenosine or unintended adenosine editing, or reduce off-target nucleotide editing. The reduction or reduction in some examples can be a reduction or reduction in the number of off-target edits or the percentage of off-target edits.

[0135] In some embodiments, the first internal loop is positioned between about 7 bases away from the A / C mismatch and about 30 bases away from the A / C mismatch, relative to the base of the first internal loop that is closest to the A / C mismatch. In some embodiments, the first internal loop is positioned between about 10 bases away from the A / C mismatch, relative to the base of the first internal loop that is closest to the A / C mismatch. In some embodiments, the second internal loop is positioned between about 18 bases away from the A / C mismatch and about 34 bases away from the A / C mismatch, relative to the base of the second internal loop that is closest to the A / C mismatch. In some embodiments, the second internal loop is positioned between about 34 bases away from the A / C mismatch, relative to the base of the second internal loop that is closest to the A / C mismatch.

[0136] Each of the first and second internal loops of the barbell macrofootprint can be independently symmetric or asymmetric, where the symmetry is determined by the number of bases or nucleotides of the engineered guide RNA and the number of bases or nucleotides of the target RNA that together form each of the first and second internal loops.

[0137] As described herein, a double-stranded RNA (dsRNA) substrate (guide-target RNA scaffold) is formed upon hybridization of an engineered guide RNA of the present disclosure to a LRRK2 target RNA. The internal loop can be a symmetric internal loop or an asymmetric internal loop. A "symmetric internal loop" is formed when the same number of nucleotides are present on both sides of the internal loop. For example, a symmetric internal loop of a guide-target RNA scaffold of the present disclosure can have the same number of nucleotides on the engineered guide RNA side and the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 5 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure can be formed by 6 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 6 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 7 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 7 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 8 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 8 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 9 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 9 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 10 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold target and 10 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 15 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 15 nucleotides on the target RNA side of the guide-target RNA scaffold. The symmetric internal loop of the present disclosure can be formed by 20 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 20 nucleotides on the target RNA side of the guide-target RNA scaffold.A symmetric internal loop of the present disclosure may be formed by 30 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 30 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 40 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 40 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 50 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 60 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 60 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 70 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 70 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 80 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 80 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 90 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 90 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 100 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 110 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 110 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 120 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 120 nucleotides on the target RNA side of the guide-target RNA scaffold.A symmetric internal loop of the present disclosure may be formed by 130 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 130 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 140 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 140 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 150 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 150 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 200 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 250 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 250 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 300 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 350 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 350 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 400 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 450 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 450 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 500 nucleotides on the target RNA side of the guide-target RNA scaffold.A symmetric internal loop of the present disclosure may be formed by 600 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 600 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 700 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 700 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 800 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 800 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 900 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 900 nucleotides on the target RNA side of the guide-target RNA scaffold. A symmetric internal loop of the present disclosure may be formed by 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold target and 1000 nucleotides on the target RNA side of the guide-target RNA scaffold. Thus, the symmetric internal loop may be a structural feature formed from the potential structures provided by the engineered potential guide RNA.

[0138] As described herein, a double-stranded RNA (dsRNA) substrate (e.g., a guide-target RNA scaffold) is formed upon hybridization of an engineered guide RNA of the present disclosure to a LRRK2 target RNA. The internal loop can be a symmetric internal loop or an asymmetric internal loop. An "asymmetric internal loop" is formed when a different number of nucleotides are present on both sides of the internal loop. For example, an asymmetric internal loop in a guide-target RNA scaffold of the present disclosure can have a different number of nucleotides on the engineered guide RNA side and the target RNA side of the guide-target RNA scaffold.

[0139] The asymmetric internal loop of the present disclosure may be formed by 5-150 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold and 5-150 nucleotides on the target RNA side of the guide-target RNA scaffold, where the number of nucleotides on the engineered side of the guide-target RNA scaffold target is different compared to the number of nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5-1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold and 5-1000 nucleotides on the target RNA side of the guide-target RNA scaffold, where the number of nucleotides on the engineered side of the guide-target RNA scaffold target is different compared to the number of nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and 6 nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 6 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and 7 nucleotides on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 7 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and an 8 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 8 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by a 5 nucleotide internal loop on the engineered guide RNA side of the guide-target RNA scaffold and a 9 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 9 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and a 10 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and a 10 nucleotide internal loop on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 6 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and a 7 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 6 nucleotides on the target RNA side of the guide-target RNA scaffold and a 7 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 6 nucleotide on the engineered guide RNA side of the guide-target RNA scaffold and an 8 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 6 nucleotide on the target RNA side of the guide-target RNA scaffold and an 8 nucleotide on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 6 nucleotide on the engineered guide RNA side of the guide-target RNA scaffold and a 9 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 6 nucleotide on the target RNA side of the guide-target RNA scaffold and a 9 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 6 nucleotide on the engineered guide RNA side of the guide-target RNA scaffold and a 10 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 6 nucleotides on the target RNA side of the guide-target RNA scaffold and 10 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure may be formed by a 7 nucleotide on the engineered guide RNA side of the guide-target RNA scaffold and an 8 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 7 nucleotide on the target RNA side of the guide-target RNA scaffold and an 8 nucleotide on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 7 nucleotide on the engineered guide RNA side of the guide-target RNA scaffold and a 9 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 7 nucleotide on the target RNA side of the guide-target RNA scaffold and a 9 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 7 nucleotide on the engineered guide RNA side of the guide-target RNA scaffold and a 10 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 7 nucleotides on the target RNA side of the guide-target RNA scaffold and 10 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 8 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and a 9 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 8 nucleotides on the target RNA side of the guide-target RNA scaffold and 9 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 8 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold and a 10 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 8 nucleotides on the target RNA side of the guide-target RNA scaffold and 10 nucleotides on the engineered guide RNA side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure may be formed by a 9 nucleotide internal loop on the engineered guide RNA side of the guide-target RNA scaffold and a 10 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 9 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold and a 10 nucleotide internal loop on the engineered guide RNA side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 5 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold and a 50 nucleotide internal loop on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 5 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold and a 100 nucleotide internal loop on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by a 5 nucleotide internal loop on the target RNA side of the guide-target RNA scaffold and a 150 nucleotide internal loop on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 5 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure may be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 150 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure may be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 50 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 50 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 150 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure can be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure may be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 100 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 100 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure may be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 150 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 150 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 5 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 150 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 150 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure may be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 200 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 200 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 300 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold.The asymmetric internal loop of the present disclosure may be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 300 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 400 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 400 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 500 nucleotides on the target RNA side of the guide-target RNA scaffold and 1000 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. The asymmetric internal loop of the present disclosure may be formed by 1000 nucleotides on the target RNA side of the guide-target RNA scaffold and 500 nucleotides on the engineered polynucleotide side of the guide-target RNA scaffold. Thus, the asymmetric internal loop may be a structural feature formed from a potential structure provided by a potential engineered guide RNA.

[0140] In some embodiments, the first internal loop or the second internal loop, independently, is at least about 5 bases or more (e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150); about 150 bases or less (e.g., 145, 135, 125, 115, 95, 85, 75, 65, 55, 45, 35, 25, 19, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150); 8, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5); or at least about 5 bases to at least about 150 bases (e.g., 5-150, 6-145, 7-140, 8-135, 9-130, 10-125, 11-120, 12-115, 13-110, 14-105, 15-100, 16-95, 17-90, 18-85, 19-80, 20-75, 21-70, 22-65, 23-60, 24-55, 25-50) and an engineered guide RNA of at least about 5 bases or more (e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150); about 150 bases or less (e.g., 145, 135, 125, 115, 95, 85, 75, 65, 55, 45, 35, 25, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5); or at least about 5 bases to at least about 150 bases (e.g., 5 to 150, 6 to 145, 7 to 140, 8 to 135, 9 to 130, 10 to 125, 11 to 120, 12 to 115, 13 to 110, 14 to 105, 15 to 100, 16 to 95, 17 to 90, 18 to 85, 19 to 80, 20 to 75, 21 to 70, 22 to 65, 23 to 60, 24 to 55, 25 to 50).

[0141] In some embodiments, an engineered guide RNA that includes a barbell macrofootprint (e.g., a potential structure that appears as a first internal loop and a second internal loop) includes a cytosine in a microfootprint sequence between the macrofootprint sequences that is opposite an adenosine (e.g., an on-target adenosine) that is edited by the RNA editing entity in the guide-target RNA scaffold when the engineered guide RNA hybridizes to the LRRK2 target RNA. In such embodiments, the cytosine in the microfootprint is included in an A / C mismatch with the on-target adenosine of the target RNA of the guide-target RNA scaffold.

[0142] The first and second internal loops of the barbell macro footprint may be positioned at a fixed distance from the A / C mismatch with respect to the base of the first and second internal loops closest to the A / C mismatch. In some embodiments, the first and second internal loops may be positioned at the same number of bases away from the A / C mismatch with respect to the base of the first and second internal loops closest to the A / C mismatch. In some embodiments, the first and second internal loops may be positioned at different numbers of bases away from the A / C mismatch with respect to the base of the first and second internal loops closest to the A / C mismatch.

[0143] In some embodiments, the barbell first internal loop or the barbell second internal loop can be positioned at least about 5 bases (e.g., 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 bases) away from the A / C mismatch with respect to the base of the first internal loop or the second internal loop closest to the A / C mismatch. In some embodiments, the barbell first internal loop or the barbell second internal loop can be positioned up to about 50 bases (e.g., 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5 bases) away from the A / C mismatch with respect to the base of the first internal loop or the second internal loop closest to the A / C mismatch.

[0144] In some embodiments, the first internal loop can be positioned about 5 bases away from the A / C mismatch to about 15 bases away from the A / C mismatch (e.g., 6-14, 7-13, 8-12, 9-11 bases away) with respect to the base of the first internal loop closest to the A / C mismatch. In some examples, the first internal loop can be positioned about 9 bases away from the A / C mismatch to about 15 bases away from the A / C mismatch (e.g., 10-14, 11-13 bases away) with respect to the base of the first internal loop closest to the A / C mismatch.

[0145] In some embodiments, the second internal loop can be positioned from about 12 bases away from the A / C mismatch to about 40 bases away from the A / C mismatch (e.g., 13-39, 14-38, 15-37, 16-36, 17-35, 18-34, 19-33, 20-32, 21-31, 22-30, 23-29, 24-28, 25-27 bases away) with respect to the base of the second internal loop closest to the A / C mismatch. In some embodiments, the second internal loop can be positioned from about 20 bases away from the A / C mismatch to about 33 bases away from the A / C mismatch with respect to the base of the second internal loop closest to the A / C mismatch. [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11] [Table 1-12]

Table 1-13

Table 1-14

Table 1-15

Table 1-16

Table 1-17

Table 1-18

Table 1-19

Table 1-20

Table 1-21

Table 1-22

Table 1-23

Table 1-24

Table 1-25

Table 1-26

[0146] Target and disposal method Also disclosed herein is a method for treating a subject by administering LRRK2 targeting guide RNA or its encoding polynucleotide.Administering LRRK2 targeting guide RNA as described herein can be used to treat LRRK2 mutation-related disease or condition (e.g., Parkinson's disease or Crohn's disease) as described herein.

[0147] Proinflammatory signals upregulate LRRK2 expression in various immune cell types, suggesting that LRRK2 is a key regulator of immune responses. Studies have shown that Parkinson's disease symptoms involve both systemic and central nervous system (CNS) inflammation. Furthermore, LRRK2 mutations associated with Parkinson's disease regulate their expression levels in response to inflammatory stimuli. Many mutations in LRRK2 are associated with immune-related disorders, e.g., inflammatory bowel disease, such as Crohn's disease. For example, G2019S and N2081D both increase the kinase activity of LRRK2 and are overrepresented in certain populations of Crohn's disease patients. Due to its important role in these disorders, LRRK2 has become an important therapeutic target for Parkinson's disease and Crohn's disease. In particular, many mutations, such as point mutations including G2019S, have been implicated in the development of these diseases, making LRRK2 attractive for therapeutic strategies such as RNA editing.

[0148] In some embodiments, the present disclosure provides compositions and methods of use of guide RNAs capable of promoting RNA editing of LRRK2. In some embodiments, the guide RNAs of the present disclosure are capable of promoting the following mutations in LRRK2: E10L, A30P, S52F, E46K, A53T, L119P, A211V, C228S, E334K, N363S, V366M, A419V, R506Q, N544E, N551K, A716V, M712V, I723V, P755L, R793M, I810V, K871E, Q923H, Q930R, R1067Q, S1096C, Q1111H, I1122V, A1151T , L1165P, I1192V, H1216R, S1228T, P1262A, R1325Q, I1371V, R1398H, T1410M, D1420N , R1441G, R1441H, A1442P, P1446L, V1450I, K1468E, R1483Q, R1514Q, P1542S, V1613A , R1628P, M1646T, S1647T, Y1699C, R1728H, R1728L, L1795F, M1869V, M1869T, L1870F , E1874X, R1941H, Y2006H, I2012T, G2019S, I2020T, T2031S, N2081D, T2141M, R2143H, Y2189C, T2356I, G2385R, V2390M, E2395K, M2397T, L2466H, or Q2490NfsX3. The guide RNA targeting a site in LRRK2 can be encoded by an engineered polynucleotide construct of the present disclosure.

[0149] The guide RNA targeting a site in LRRK2 may be encoded by an engineered polynucleotide construct of the present disclosure. The engineered guide RNA targeting LRRK2 may comprise any of the polynucleotides of the sequences listed in Table 1 provided in this disclosure. The engineered guide RNA targeting LRRK2 may comprise any of the polynucleotides of the sequences listed in Table 2 provided in this disclosure. The engineered guide RNA targeting LRRK2 may comprise any of the polynucleotides of the sequences listed in Table 3 provided in this disclosure. The engineered guide RNA targeting LRRK2 may comprise any of the polynucleotides of the sequences listed in Table 4 provided in this disclosure. The engineered guide RNA targeting LRRK2 may comprise any of the polynucleotides of the sequences listed in Table 5 provided in this disclosure. The engineered guide RNA targeting LRRK2 may comprise any of the polynucleotides of the sequences listed in Table 6 provided in this disclosure. The engineered guide RNA targeting LRRK2 may comprise any of the polynucleotides of the sequences listed in Table 7 provided in this disclosure. An engineered guide RNA targeting LRRK2 may comprise any of the polynucleotides of the sequences listed in Table 8 provided herein. An engineered guide RNA targeting LRRK2 may comprise any of the polynucleotides of the sequences listed in Table 9 provided herein.

[0150] The guide RNA targeting LRRK2 may comprise any one of SEQ ID NO:2-395 or SEQ ID NO:398-472. In some examples, the engineered guide comprises a polynucleotide having at least 99% identity, at least 95% identity, at least 90% identity, at least 85% identity, at least 80% identity, or at least 70% identity to any one of SEQ ID NO:2-395 or SEQ ID NO:398-472. In some examples, the engineered guide comprises a polynucleotide having at least 99% length, at least 95% length, at least 90% length, at least 85% length, at least 80% length, or at least 70% length to any one of SEQ ID NO:2-395 or SEQ ID NO:398-472 above. Furthermore, the guide RNA targeting LRRK2 may comprise a sequence having a portion of any one of SEQ ID NO:2-395 or SEQ ID NO:398-472. In some examples, the engineered guide comprises a polynucleotide having a portion of any one of SEQ ID NO:2-SEQ ID NO:395 or SEQ ID NO:398-SEQ ID NO:472. In some examples, the engineered guide comprises a polynucleotide having a portion of any one of SEQ ID NO:5, SEQ ID NO:23, SEQ ID NO:32, SEQ ID NO:38, or SEQ ID NO:50. In some examples, the engineered guide comprises a polynucleotide having a portion of SEQ ID NO:5. In some examples, the engineered guide comprises a polynucleotide having a portion of SEQ ID NO:23. In some examples, the engineered guide comprises a polynucleotide having a portion of SEQ ID NO:32. In some examples, the engineered guide comprises a polynucleotide having a portion of SEQ ID NO:38. In some examples, the engineered guide comprises a polynucleotide having a portion of SEQ ID NO:50. In some examples, the engineered guide comprises a polynucleotide having at least 20-50 contiguous nucleotides derived from a portion of any one of SEQ ID NO:2-SEQ ID NO:395 or SEQ ID NO:398-SEQ ID NO:472.In some examples, the engineered guide comprises a polynucleotide having at least 20-50 contiguous nucleotides derived from a portion of any one of SEQ ID NO:5, SEQ ID NO:23, SEQ ID NO:32, SEQ ID NO:38, or SEQ ID NO:50. In some examples, the engineered guide comprises a polynucleotide having 20-50 contiguous nucleotides derived from a portion of SEQ ID NO:5. In some examples, the engineered guide comprises a polynucleotide having 20-50 contiguous nucleotides derived from a portion of SEQ ID NO:23. In some examples, the engineered guide comprises a polynucleotide having 20-50 contiguous nucleotides derived from a portion of SEQ ID NO:32. In some examples, the engineered guide comprises a polynucleotide having 20-50 contiguous nucleotides derived from a portion of SEQ ID NO:38. In some examples, the engineered guide comprises a polynucleotide having 20-50 contiguous nucleotides derived from a portion of SEQ ID NO:50. In some examples, the engineered guide comprises a polynucleotide having 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 consecutive nucleotides derived from a portion of any one of SEQ ID NO:2-SEQ ID NO:395 or SEQ ID NO:398-SEQ ID NO:472. In some examples, the engineered guide comprises a polynucleotide having 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 consecutive nucleotides derived from a portion of any one of SEQ ID NO:5, SEQ ID NO:23, SEQ ID NO:32, SEQ ID NO:38, or SEQ ID NO:50. In some examples, the engineered guide comprises a polynucleotide having 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 consecutive nucleotides from a portion of SEQ ID NO:5.In some examples, the engineered guide comprises a polynucleotide having 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 consecutive nucleotides derived from a portion of SEQ ID NO: 23. In some examples, the engineered guide comprises a polynucleotide having 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 consecutive nucleotides derived from a portion of SEQ ID NO: 32. In some examples, the engineered guide comprises a polynucleotide having 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 consecutive nucleotides derived from a portion of SEQ ID NO: 38. In some examples, the engineered guide comprises a polynucleotide having 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 consecutive nucleotides derived from a portion of SEQ ID NO: 50. The engineered guide RNA can be delivered by a viral vector as disclosed herein (e.g., encoded and delivered by AAV) and can be administered to a subject in need thereof via any of the administration routes disclosed herein. The subject can be a human and can be at risk of developing or has a disease or condition associated with LRRK2 (e.g., Parkinson's disease or Crohn's disease). Such a disease or condition can be caused, at least in part, by a mutation in LRRK2, and the engineered guide RNA described herein can promote its editing, thereby correcting the mutation in LRRK2 and reducing the incidence of the disease or condition in the subject.Thus, the guide RNAs of the present disclosure can be used in methods for treating diseases such as Crohn's disease or Parkinson's disease.

[0151] Pharmaceutical Compositions The engineered guide RNAs targeting LRRK2 described herein (e.g., guide RNAs having a polynucleotide sequence of any one of SEQ ID NO:2-SEQ ID NO:395 or SEQ ID NO:398-SEQ ID NO:472) or polynucleotides encoding the engineered guide RNAs described herein are formulated with a pharma- ceutically acceptable carrier for administration to a subject (e.g., a human or non-human animal). Pharmaceutically acceptable carriers may include, but are not limited to, phosphate buffered saline, water, emulsions (e.g., oil / water emulsions or water / oil emulsions), glycerol, liquid polyethylene glycols, aprotic solvents (e.g., dimethylsulfoxide, N-methylpyrrolidone, or mixtures thereof), and various types of wetting agents, solubilizers, antioxidants, bulking agents, protein carriers such as albumin, any solvents, dispersion media, coatings, sodium lauryl sulfate, isotonic agents, and absorption retarders, disintegrants (e.g., potato starch or sodium starch glycolate), and the like. The compositions may also include stabilizers and preservatives. Additional examples of carriers, stabilizers, and adjuvants compatible with the compositions of the present disclosure can be found, for example, in Remington's Pharmaceutical Sciences, 21st Ed., Mack Publ. Co., Easton, Pa. (2005), which is incorporated by reference in its entirety.

[0152] delivery The engineered guide RNAs targeting LRRK2 described herein (e.g., guide RNAs having a polynucleotide sequence of any one of SEQ ID NO:2-SEQ ID NO:395 or SEQ ID NO:398-SEQ ID NO:472) or polynucleotides encoding the engineered guide RNAs described herein can be delivered by a delivery vehicle. In some embodiments, the delivery vehicle is a vector. The vector can facilitate delivery of the engineered guide RNA to a cell to genetically modify the cell. In some examples, the vector comprises DNA, e.g., double-stranded or single-stranded DNA. In some examples, the delivery vector can be a eukaryotic vector, a prokaryotic vector (e.g., a bacterial vector or a plasmid), a viral vector, or any combination thereof. In some embodiments, the vector is an expression cassette. In some embodiments, the viral vector comprises a viral capsid, an inverted terminal repeat, and the engineered polynucleotide can be used to deliver the engineered guide RNA to a cell.

[0153] In some embodiments, the viral vector can be a retroviral vector, an adenoviral vector, an adeno-associated viral (AAV) vector, an alphavirus vector, a lentiviral vector (e.g., human or porcine), a herpes virus vector, an Epstein-Barr virus vector, an SV40 viral vector, a pox virus vector, or a combination thereof. In some embodiments, the viral vector can be a recombinant vector, a hybrid vector, a chimeric vector, a self-complementary vector, a single-stranded vector, or any combination thereof.

[0154] In some embodiments, the viral vector can be an adeno-associated virus (AAV). In some embodiments, the AAV can be any AAV known in the art. In some embodiments, the viral vector can be of a specific serotype. In some embodiments, the viral vector is selected from the group consisting of AAV1 serotype, AAV2 serotype, AAV3 serotype, AAV4 serotype, AAV5 serotype, AAV6 serotype, AAV7 serotype, AAV8 serotype, AAV9 serotype, AAV10 serotype, AAV11 serotype, AAV12 serotype, AAV13 serotype, AAV14 serotype, AAV15 serotype, AAV16 serotype, AAV.rh8 serotype, AAV.rh10 serotype, AAV.rh20 serotype, AAV.rh39 serotype, AAV.Rh74 serotype, AAV.RHM4-1 serotype, AAV.hu37 serotype, AAV.Anc80 serotype, AAV.Anc80L65 serotype, AAV.7m8 serotype, AAV.PHP.B serotype , AAV2.5 serotype, AAV2tYF serotype, AAV3B serotype, AAV.LK03 serotype, AAV.HSC1 serotype, AAV.HSC2 serotype, AAV.HSC3 serotype, AAV.HSC4 serotype, AAV.HSC5 serotype, AAV.HSC6 serotype, AAV.HSC7 serotype, AAV.HSC8 serotype, AAV.HSC9 serotype, AAV.HSC10 serotype, AAV.HSC11 serotype, AAV.HSC12 serotype, AAV.HSC13 serotype, AAV.HSC14 serotype, AAV.HSC15 serotype, AAV.HSC16 serotype, and AAVhu68 serotype, derivatives of any of these serotypes, or any combination thereof.

[0155] In some embodiments, the AAV vector can be a recombinant vector, a hybrid AAV vector, a chimeric AAV vector, a self-complementary AAV (scAAV) vector, a single-stranded AAV, or any combination thereof.

[0156] In some embodiments, the AAV vector may be a recombinant AAV (rAAV) vector. Methods for producing recombinant AAV vectors may be known in the art and in some cases typically include introducing into a producer cell line a plasmid construct that includes (1) the DNA required for AAV replication and synthesis of AAV capsid, (b) one or more helper constructs that contain viral functions that are missing from the AAV vector, (c) a helper virus, and (d) the genome of the AAV vector, such as ITRs, a promoter, and an engineered guide RNA sequence. In some examples, the viral vectors described herein may be engineered by synthesis or other suitable means with reference to published sequences, such as those that may be available in the literature. For example, the genome and protein sequences of various serotypes of AAV, as well as the sequences of natural terminal repeats (TRs), Rep proteins, and capsid subunits, may be known in the art and may be found in the literature or public databases, such as GenBank or the Protein Data Bank (PDB).

[0157] In some examples, the method of generating a delivery vector herein includes packaging an engineered guide RNA or an engineered polynucleotide (e.g., an engineered polynucleotide encoding an engineered guide RNA) of the present disclosure into an AAV vector. In some examples, the method of generating a delivery vector described herein includes (a) introducing into a cell (i) a polynucleotide comprising a promoter and an engineered guide RNA payload disclosed herein; and (ii) a viral genome comprising a replication (Rep) gene and a capsid (Cap) gene encoding a wild-type AAV capsid protein or a modified version thereof; (b) expressing the wild-type AAV capsid protein or a modified version thereof in the cell; (c) assembling an AAV particle; and (d) packaging the payload disclosed herein into the AAV particle, thereby generating an AAV delivery vector. In some examples, the recombinant vector includes one or more terminal inverted repeats, and the terminal inverted repeats include a 5' terminal inverted repeat, a 3' terminal inverted repeat, and a mutated terminal inverted repeat. In some instances, the variant terminal repeat sequence lacks a terminal release site, thereby allowing the formation of a self-complementary AAV.

[0158] In some examples, a hybrid AAV vector can be produced by capsid swapping, e.g., packaging an inverted terminal repeat (ITR) from a first serotype into a capsid of a second serotype, where the first and second serotypes may not be the same. In some examples, a Rep gene and ITR from a first AAV serotype (e.g., AAV2) can be used in a capsid from a second AAV serotype (e.g., AAV5 or AAV9), where the first and second AAV serotypes may not be the same. As a non-limiting example, a hybrid AAV serotype comprising AAV2 ITRs and AAV9 capsid proteins can be designated AAV2 / 9. In some examples, a hybrid AAV delivery vector comprises an AAV2 / 1, AAV2 / 2, AAV2 / 4, AAV2 / 5, AAV2 / 8, or AAV2 / 9 vector.

[0159] In some examples, the AAV vector can be a chimeric AAV vector. In some examples, the chimeric AAV vector comprises foreign amino acids or amino acid substitutions, or capsid proteins from two or more serotypes. In some examples, the chimeric AAV vector can be engineered to increase transduction efficiency, selectivity, or a combination thereof.

[0160] In some instances, the AAV vector comprises a self-complementary AAV genome, which may be generally known in the art and may contain both DNA strands that can anneal to each other to form double-stranded DNA.

[0161] In some examples, the delivery vector can be a retroviral vector. In some examples, the retroviral vector can be a Moloney murine leukemia virus vector, a spleen necrosis virus vector, or a vector derived from Rous sarcoma virus, Harvey sarcoma virus, avian leukosis virus, human immunodeficiency virus, myeloproliferative sarcoma virus, or mammary tumor virus, or a combination thereof. In some examples, the retroviral vector can be transfected such that most of the sequences encoding the viral structural genes (e.g., gag, pol, and env) can be removed and replaced with the gene(s) of interest.

[0162] In some examples, the delivery vehicle may be a non-viral vector. In some examples, the delivery vehicle may be a plasmid. In some embodiments, the plasmid comprises DNA. In some examples, the plasmid comprises circular double-stranded DNA. In some examples, the plasmid may be linear. In some examples, the plasmid comprises one or more genes of interest and one or more regulatory elements. In some examples, the plasmid comprises a bacterial backbone including an origin of replication, and an antibiotic resistance gene or other selection marker for plasmid amplification in bacteria. In some examples, the plasmid may be a minicircle plasmid. In some examples, the plasmid contains one or more genes that provide a selection marker for introducing and retaining the plasmid in target cells. In some examples, the plasmid may be formulated for delivery by injection with a syringe equipped with a needle. In some examples, the plasmid may be formulated for delivery by electroporation. In some examples, the plasmid may be genetically engineered by synthesis or other suitable means known in the art. For example, in some cases, genetic elements can be assembled by restriction digestion of a desired genetic sequence from a donor plasmid or organism to generate DNA ends that can then be easily ligated to another genetic sequence.

[0163] In some embodiments, the vector containing engineered guide RNA or engineered polynucleotide is a non-viral vector system.In some embodiments, the non-viral vector system comprises cationic lipid or polymer.For example, the non-viral vector system can be liposome or polymer nanoparticle.In some embodiments, the non-viral vector containing engineered polynucleotide or engineered guide RNA or engineered polynucleotide is delivered to cells by hydrodynamic injection or ultrasound.

[0164] Administration Administration refers to methods that can be used to enable delivery of an engineered guide RNA targeting LRRK2 described herein (e.g., a guide RNA having a polynucleotide sequence of any one of SEQ ID NO:2-SEQ ID NO:395 or SEQ ID NO:398-SEQ ID NO:472) or a polynucleotide encoding an engineered guide RNA described herein to a desired biological site of action. For example, the engineered guide RNA can be included in a DNA construct, a viral vector, or both, and can be administered by intravenous administration. Administration as disclosed herein to an area in need of treatment or therapy can be accomplished, for example, but not limited to, by oral administration, topical administration, intravenous administration, inhalation administration, or any combination thereof. In some embodiments, delivery includes inhalation, auricular, intraoral, conjunctival, dental, intracervical, intranasal, intratracheal, enteral, epidural, extra-amniotic, extracorporeal, hemodialysis, infiltrating, interstitial, intra-abdominal, intra-amniotic, intra-arterial, intra-articular, intra-biliary, intra-bronchial, intra-synovial, intracardiac, intracartilage, intra-caudal, intracavernous, intraluminal, intraventricular, intracisternal, intracorneal, intracoronary, intracoronary, intracavernous, intradermal, intradiscal, intraductal, intraduodenal, intradural, intraepidermal, intraesophageal, intragastric, intragingival, intrahippocampal, intraileal, intralesional, intraluminal, intralymphatic, intramedullary, intrameningeal, intramuscular, intraocular, intraovarian, intrapericardial, intraperitoneal, intrapleural. , intraprostatic, intrapulmonary, intrasinus, intraspinal, intrasynovial, intratendon, intratesticular, intrathoracic, intracanalicular, intratumoral, intratympanic, intrauterine, intravascular, intravenous, intravenous bolus, intravenous infusion, intravesical, intravitreal, iontophoresis, irrigation, laryngeal, nasal, nasogastric, ophthalmic, oral, oropharyngeal, parenteral, transdermal, periarticular, epidural, perineural, periodontal, rectal, retrobulbar, subarachnoid, subconjunctival, subcutaneous, sublingual, submucosal, topical, transdermal, transmucosal, transplacental, transtracheal, transtympanic, ureteral, urethral, ​​vaginal, infraorbital, intraparenchymal, intrathecal, intraventricular, stereotactic, or any combination thereof. Delivery may include parenteral administration (including intravenous, subcutaneous, intrathecal, intraperitoneal, intramuscular, intravascular, or infusion), oral administration, inhalation administration, intraduodenal administration, rectal administration, or combinations thereof. Delivery may include direct application to the affected tissue or area of ​​the body.In some cases, local administration may include administering lotions, solutions, emulsions, creams, balms, oils, pastes, sticks, aerosols, foams, jellies, foams, masks, pads, powders, solids, tinctures, butters, patches, gels, sprays, drops, liquid formulations, ointments to the external surface of a surface such as the skin. Delivery may include injection into the parenchyma, intraspinal injection, intraventricular injection, or intracisternal injection. The compositions provided herein may be administered by any method. Administration may be by intraarterial injection, intracisternal injection, intramuscular injection, intraparenchymal injection, intraperitoneal injection, intraspinal injection, intrathecal injection, intravenous injection, intraventricular injection, stereotactic injection, subcutaneous injection, epidural, or any combination thereof. Delivery may include parenteral administration, including intravenous, subcutaneous, intrathecal, intraperitoneal, intramuscular, intravascular, or infusion administration. In some embodiments, delivery may include nanoparticles, liposomes, exosomes, extracellular vesicles, implants, or combinations thereof. In some cases, delivery may be from a device. In some examples, delivery may be performed by a pump, an infusion pump, or a combination thereof. In some embodiments, delivery may be by an enema, eye drops, nasal spray, or any combination thereof. In some examples, the subject may administer the composition in the absence of supervision. In some examples, the subject may administer the composition under the supervision of a medical professional (e.g., a doctor, a nurse, a medical assistant, a janitor, a hospice worker, etc.). In some embodiments, a medical professional may administer the composition.

[0165] In some cases, administering can be oral ingestion. In some cases, delivery can be capsules or tablets. Oral ingestion delivery can include tea, elixir, food, drink, beverage, syrup, liquid, gel, capsule, tablet, oil, tincture, or any combination thereof. In some embodiments, the food can be a medical food. In some examples, the capsule can include hydroxymethylcellulose. In some embodiments, the capsule can include gelatin, hydroxypropylmethylcellulose, pullulan, or any combination thereof. In some cases, the capsule can include a coating, for example, an enteric coating. In some embodiments, the capsule can include vegetarian or vegan products, such as hypromellose capsules. In some embodiments, delivery can include inhalation by inhaler, diffuser, nebulizer, vaporizer, or any combination thereof.

[0166] In some embodiments, methods may be disclosed herein that include administering a composition disclosed herein to a subject (e.g., a human) in need thereof. In some examples, the methods may treat or prevent a disease in the subject.

[0167] definition Unless otherwise defined, all technical terms, notations, and other technical and scientific or technical terms used herein are generally intended to have the same meaning as commonly understood by those of ordinary skill in the art to which the claimed subject matter pertains. In some cases, terms having a commonly understood meaning are defined herein for clarity and / or ready reference, but the inclusion of such definitions herein should not necessarily be construed as indicating a substantial departure from what is commonly understood in the art.

[0168] Throughout this application, various embodiments are presented in a range format. It should be understood that the description in range format is merely for convenience and brevity and should not be construed as an inflexible limitation on the scope of the disclosure. Thus, the description of a range should be considered to specifically disclose all possible subranges and individual numerical values ​​within that range. For example, the description of a range such as 1-6 should be considered to specifically disclose subranges such as 1-3, 1-4, 1-5, 2-4, 2-6, 3-6, etc., as well as individual numbers within that range, such as 1, 2, 3, 4, 5, and 6. This applies regardless of the breadth of the range.

[0169] As used herein, the term "about" a numerical value may refer to the numerical value plus or minus 10% of the numerical value.

[0170] As disclosed herein, a "bulge" refers to a structure that is formed substantially only upon formation of the guide-target RNA scaffold, in which consecutive nucleotides of either the engineered guide RNA or the target RNA are not complementary to their corresponding positions in the opposing strand. A bulge may independently have 0-4 consecutive nucleotides on the guide RNA side of the guide-target RNA scaffold and 1-4 consecutive nucleotides on the target RNA side of the guide-target RNA scaffold, or a bulge may independently have 0-4 nucleotides on the target RNA side of the guide-target RNA scaffold and 1-4 consecutive nucleotides on the guide RNA side of the guide-target RNA scaffold. However, a bulge, as used herein, does not refer to a structure in which a single nucleotide involved in the engineered guide RNA and a single nucleotide involved in the target RNA do not base pair, and a single nucleotide involved in the engineered guide RNA and a single nucleotide involved in the target RNA that do not base pair are referred to herein as a "mismatch." Furthermore, if the number of involved nucleotides on either the guide RNA side or the target RNA side exceeds four, the resulting structure is no longer considered a bulge, but rather an "internal loop." A "symmetric bulge" refers to a bulge in which there are the same number of nucleotides on either side of the bulge. An "asymmetric bulge" refers to a bulge in which there are different numbers of nucleotides on either side of the bulge.

[0171] The term "complementary" or "complementarity" refers to the ability of a nucleic acid to form one or more bonds with a corresponding nucleic acid sequence, for example, by hydrogen bonding (e.g., conventional Watson-Crick), covalent bonding, or other similar methods. In Watson-Crick base pairing, a double hydrogen bond is formed between nucleobases T and A, while a triple hydrogen bond is formed between nucleobases C and G. For example, the sequence AGT can be complementary to the sequence TCA. Percent complementarity indicates the percentage of residues in a nucleic acid molecule that can form hydrogen bonds (e.g., Watson-Crick base pairs) with a second nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 are 50%, 60%, 70%, 80%, 90%, and 100% complementary, respectively). "Fully complementary" can mean that all consecutive residues of a nucleic acid sequence will hydrogen bond with the same number of consecutive residues of a second nucleic acid sequence. As used herein, "substantially complementary" can refer to a degree of complementarity that can be at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 100% over a region of 10, 15, 20, 25, 30, 35, 40, 45, 50 nucleotides or more, or can refer to two nucleic acids that hybridize under stringent conditions (e.g., stringent hybridization conditions). A nucleic acid can include a non-specific sequence. As used herein, the term "non-specific sequence" or "non-specific" can refer to a nucleic acid sequence that contains a series of residues that may not be designed to be complementary to any other nucleic acid sequence or may only be partially complementary to any other nucleic acid sequence.

[0172] The terms "determine," "measure," "assess," "determine," "analyze," and "analyze" may be used interchangeably herein to refer to modes of measurement. These terms include determining whether an element may be present (e.g., detection). These terms may include quantitative, qualitative, or quantitative and qualitative determinations. Evaluation may be relative or absolute. "Detecting the presence" may include determining the amount of something present, as well as determining whether it may or may not be present, depending on the context.

[0173] As used herein, the term "encode" refers to the ability of a polynucleotide to provide sufficient information or instruction sequences to produce a corresponding gene expression product. In a non-limiting example, an mRNA can encode a polypeptide upon translation, while a DNA can encode an mRNA molecule upon transcription.

[0174] "Engineered potential guide RNA" refers to an engineered guide RNA that includes a sequence portion that upon hybridization to a target RNA, or only upon hybridization, substantially forms at least a portion of the structural features other than a single A / C mismatch feature at the target adenosine to be edited.

[0175] As used herein, the term "promotes RNA editing" by engineered guide RNA refers to the ability of engineered guide RNA to associate with an RNA editing entity and a target RNA to effect targeted editing of the target RNA by the RNA editing entity. In some examples, engineered guide RNA can directly recruit or position / orient the RNA editing entity to the appropriate position for editing the target RNA. In other examples, engineered guide RNA, when hybridized to the target RNA, forms a guide-target RNA scaffold having one or more structural features as described herein, where the guide-target RNA scaffold having one or more structural features recruits or positions / orients the RNA editing entity to the appropriate position for editing the target RNA.

[0176] As disclosed herein, "guide-target RNA scaffold" is the resulting double-stranded RNA formed when hybridizing guide RNA with potential structure to target RNA.Guide-target RNA scaffold has one or more structural features that are formed in the duplex of double-stranded RNA when hybridizing.For example, guide-target RNA scaffold can have one or more structural features selected from bulge, mismatch, internal loop, hairpin or wobble base pair.

[0177] As disclosed herein, a "hairpin" includes an RNA duplex in which a portion of a single stranded RNA folds back on itself to form an RNA duplex, the portions of the single stranded RNA fold back on themselves due to having nucleotide sequences that base-pair with each other and are separated by an intervening sequence that does not base-pair with itself, thereby forming a base-paired portion and an intervening loop portion that does not base-pair.

[0178] As used herein, in the context of two or more nucleic acid or polypeptide sequences, the term "percent identity" refers to two or more sequences or subsequences that have a certain percentage of nucleotides or amino acid residues that are identical when compared and aligned for maximum correspondence, as measured using one of the sequence comparison algorithms described below (e.g., BLASTP and BLASTN or other algorithms available to those of skill in the art) or by visual inspection. Depending on the application, the percent "identity" can be over a region of the sequences being compared, e.g., a functional domain, or alternatively, over the entire length of the two sequences being compared.

[0179] For sequence comparison, typically, one sequence serves as a reference sequence to which test sequence is compared.When using sequence comparison algorithm, test sequence and reference sequence are input into computer, subsequence coordinates are designated as necessary, and sequence algorithm program parameters are designated.The sequence comparison algorithm then calculates the percent sequence identity of test sequence(s) compared to reference sequence based on the designated program parameters.

[0180] For purposes herein, percent identity and sequence similarity may be performed using the BLAST algorithm described in Altschul et al. (J. Mol. Biol. 215:403-410 (1990)). Software for performing BLAST analyses is publicly available from the National Center for Biotechnology Information.

[0181] As disclosed herein, "internal loop" refers to a structure that is formed substantially only upon formation of the guide-target RNA scaffold, in which the nucleotides of either the engineered guide RNA or the target RNA are not complementary to their corresponding positions in the opposite strand, and one side of the internal loop on either the target RNA side or the engineered guide RNA side of the guide-target RNA scaffold has 5 or more nucleotides. If the number of nucleotides involved on both the guide RNA side and the target RNA side is reduced to less than 5, the resulting structure is no longer considered an internal loop, but rather a "bulge" or a "mismatch", depending on the size of the structural feature. A "symmetric internal loop" is formed when the same number of nucleotides are present on both sides of the internal loop. An "asymmetric internal loop" is formed when a different number of nucleotides are present on both sides of the internal loop.

[0182] "Potential structure" refers to structural features that are substantially formed only when hybridizing guide RNA to target RNA.For example, the sequence of guide RNA provides one or more structural features, but these structural features are substantially formed only when hybridizing to target RNA, and thus, the one or more potential structural features appear as structural features when hybridizing to target RNA.When hybridizing guide RNA to target RNA, the structural features are formed, and thus the potential structure provided by guide RNA is revealed.

[0183] "Messenger RNA" or "mRNA" is an RNA molecule that contains a sequence that codes for a polypeptide or protein. In general, RNA can be transcribed from DNA. In some cases, a precursor mRNA that has a protein non-coding region in the sequence can be transcribed from DNA and then processed to remove all or part of the non-coding region (intron) to generate a mature mRNA. As used herein, the term "pre-mRNA" can refer to an RNA molecule that is transcribed from DNA before undergoing processing to remove the protein non-coding region.

[0184] As disclosed herein, "mismatch" refers to a single nucleotide in guide RNA that is not paired with the opposite single nucleotide in target RNA in guide-target RNA scaffold. Mismatch can include any two single nucleotides that do not base pair. If the number of involved nucleotides on the guide RNA side and the target RNA side is more than 1, the resulting structure is no longer considered a mismatch, but rather a "bulge" or "internal loop" depending on the size of the structural feature.

[0185] As used herein, the term "polynucleotide" may refer to a single- or double-stranded polymer of deoxyribonucleotide (DNA) or ribonucleotide (RNA) bases read in a 5' to 3' direction. The term "RNA" includes dsRNA (double-stranded RNA), snRNA (small nuclear RNA), lncRNA (long non-coding RNA), mRNA (messenger RNA), miRNA (microRNA), RNAi (inhibitory RNA), siRNA (small interfering RNA), shRNA (short hairpin RNA), tRNA (transfer RNA), rRNA (ribosomal RNA), snoRNA (small nucleolar RNA), and cRNA (complementary RNA). The term DNA includes cDNA, genomic DNA, and DNA-RNA hybrids.

[0186] The terms "protein", "peptide" and "polypeptide" may be used interchangeably and may refer in the broadest sense to a compound of two or more subunit amino acids, amino acid analogs, or peptidomimetics. The subunits may be linked by peptide bonds. In another embodiment, the subunits may be linked by other bonds, such as esters, ethers, and the like. A protein or peptide may contain at least two amino acids, and no limit may be placed on the maximum number of amino acids that may make up the sequence of a protein or peptide. As used herein, the term "amino acid" may refer to either natural, unnatural, or synthetic amino acids, including glycine and both D- and L-optical isomers, amino acid analogs, and peptidomimetics. As used herein, the term "fusion protein" may refer to a protein composed of domains from two or more naturally occurring or recombinantly produced proteins, where each domain generally serves a different function. In this context, the term "linker" may refer to a protein fragment that can be used to link these domains together and optionally maintain the conformation of the fused protein domains, or to prevent unfavorable interactions between the fused protein domains that could impair their respective functions, or both.

[0187] The term "structural motif" refers to the combination of two or more structural features in a guide-target RNA scaffold.

[0188] The terms "subject", "individual", or "patient" may be used interchangeably herein. "Subject" refers to a biological entity that contains expressed genetic material. The biological entity may be a plant, an animal, or a microorganism, including, for example, bacteria, viruses, fungi, and protozoa. The subject may be tissues, cells, and their progeny of the biological entity obtained in vivo or cultured in vitro. The subject may be a mammal. The mammal may be a human. The subject may be diagnosed or suspected of being at high risk for a disease. In some cases, the subject may not necessarily be diagnosed or suspected of being at high risk for a disease.

[0189] The term "in vivo" refers to events that take place within the body of a subject.

[0190] The term "ex vivo" refers to an event that occurs outside the body of a subject. An ex vivo assay may not be performed on a subject, but rather, may be performed on a sample separate from a subject. An example of an ex vivo assay performed on a sample may be an "in vitro" assay.

[0191] The term "in vitro" refers to events that occur in a container for containing laboratory reagents, such as those that can be separated from the biological source from which the material may be harvested. In vitro assays can include cell-based assays in which live or dead cells can be used. In vitro assays can also include cell-free assays in which intact cells cannot be used.

[0192] The term "wobble base pair" refers to two bases that pair weakly. For example, a wobble base pair can refer to a G paired with a U.

[0193] As used herein, the term "substantially form," when referring to a particular secondary structure, refers to the formation of at least 80% of the structure under physiological conditions (e.g., physiological pH, physiological temperature, physiological salt concentration, etc.).

[0194] As used herein, the term "treatment" or "treating" may be used in reference to a pharmaceutical or other interventional treatment regimen to achieve a beneficial or desired outcome in a recipient. A beneficial or desired outcome may include, but is not limited to, a therapeutic effect and / or a prophylactic effect. A therapeutic effect may refer to the eradication or amelioration of one or more symptoms of the underlying disease being treated. A therapeutic effect may also be achieved by eradicating or ameliorating one or more of the physiological symptoms associated with the underlying disease, such that an improvement may be observed in the subject, even though the subject may still be afflicted with the underlying disease. A prophylactic effect may include delaying, preventing, or eliminating the appearance of a disease or condition, delaying or eliminating the onset of one or more symptoms of a disease or condition, slowing, halting, or reversing the progression of a disease or condition, or any combination thereof. A subject at risk of developing a particular disease or reporting one or more of the physiological symptoms of a disease may receive treatment for a prophylactic effect, even if the disease has not been diagnosed. EXAMPLES

[0195] The following illustrative examples represent embodiments of the stimuli, systems, and methods described herein and are not intended to be limiting in any way.

[0196] Example 1 High-throughput screening of engineered guide RNAs targeting LRRK2 mRNA Using the compositions and methods described herein, a high-throughput screen (HTS) of long engineered guide RNAs (e.g., 100-mer or longer) targeting LRRK2 mRNA was performed. The engineered guide RNAs form microfootprints in the guide-target RNA scaffold that contain various structural features, and a barbell macrofootprint that contains two 6 / 6 internal loops near both ends of the guide-target RNA scaffold. Furthermore, in this high-throughput screen, the self-annealing RNA structure was sized (231 nucleotides) to allow the screening of engineered guide RNAs of 113 nucleotides in length, and the target adenosine to be edited was located at the 57th nucleotide. This high-throughput screen allowed the identification of engineered guide RNAs that showed high on-target adenosine editing (>60%, 30 min incubation with ADAR1 and ADAR2) and little or no local off-target adenosine editing (e.g., at position -2 relative to the target adenosine at position 0 to be edited). Self-annealing RNA structures that form barbell macrofootprints on the guide-target RNA scaffold were screened to contain four distinct microfootprints (A / C mismatch (ATTCTACAGCAGTACTGAGCAATGCCGTAGTCAGCAATCTTTGCA (SEQ ID NO: 102)), 2108 (ATTCTACGGCGGTACTGACCAATCCCGTAGTTAGCAATCTTTGCA (SEQ ID NO: 103), 871 (ATTCTACAGTAGGACTGAGCACTGCCGAGCTGGGCAATCTTTGCA (SEQ ID NO: 104)), and 919 (CTTCTACAGCAGTTCGGAGGAATCCCGAGGTCAGCAATCTTTGCA (SEQ ID NO: 105)), with the barbell macrofootprint positions aligned from position -22 to position -12 at one end of the self-annealing RNA structure and from position +12 to position +34 at the other end of the self-annealing RNA structure.Self-annealing RNA constructs containing 1939 different guide RNA sequences and sequences of regions targeted by the guide RNAs were contacted with RNA editing entities (e.g., recombinant ADAR1 and / or ADAR2) for 30 minutes under conditions that allow editing of the regions targeted by the guide RNAs. Editing of the regions targeted by the guide RNAs was then assessed using next generation sequencing (NGS).

[0197] Libraries for screening these long engineered guides were generated as follows, as summarized in Figure 2. A candidate engineered guide library was obtained with a construct containing a T7 promoter, followed by the candidate engineered guide RNA sequence to be tested, followed by an Illumina R2 hairpin, followed by sequences for USER (Uracil-specific removal reagent) site overlap. The library and target sequences were amplified by PCR to incorporate deoxyuridine (dU) at the 3' end of the construct containing the candidate engineered guide RNA sequence and at the 5' end of the target. The PCR amplified library and target were then incubated with USER enzyme to allow nicking at the dU position and ligation (using Taq ligase) to the target sequence of a given library construct containing the candidate engineered guide RNA sequence.

[0198] FIG. 3 shows a comparison of cell-free RNA editing using the methods and compositions described herein with intracellular RNA editing facilitated via the same engineered guide RNA sequence at various time points (20 seconds, 1 minute, 3 minutes, 10 minutes, 30 minutes, and 60 minutes). In this experiment, 40 guide RNA candidates were screened. Each cell had 50 nM ADAR1 + 100 nM ADAR2. The editing value of each guide and the location of the edited adenosine are shown in FIG. 3 as a cumulative value of six values. Open circles represent on-target adenosine editing for each guide, and closed circles represent editing of adenosines other than the on-target adenosine (off-target adenosine). Overall, these data show that a good correlation can be obtained between cell-free high-throughput screening and intracellular RNA editing, especially at certain time points (e.g., 30 minutes).

[0199] Figure 4 shows a heat map of all self-annealing RNA structures tested on the four microfootprints formed within various configurations of the barbell macrofootprint. The y-axis shows all engineered guide RNAs tested, and the x-axis shows the position of the target sequence. Position 0 represents the target adenosine to be edited.

[0200] Exemplary engineered guide RNAs obtained from the high-throughput screening of this example are listed in Table 2. The engineered guide RNA candidates in Table 2 showed specific editing of the A nucleotide at position 6055 of the mRNA encoding LRRK2 G2019S. On-target editing percentage is calculated by the following formula: number of reads containing "G" in the target / total number of reads. Specificity is calculated by the following formula: (percentage of on-target editing + 100) / (sum of off-target editing percentages at selected off-target sites + 100). Addition of barbells resulted in specific editing patterns. In particular, the presence of barbells at positions -14 and +26 seemed to increase the specificity of ADAR editing. Thus, the combination of microfootprint structural features with macrofootprint structural features such as barbells can significantly improve specificity. [Table 2-1] [Table 2-2] [Table 2-3] [Table 2-4] [Table 2-5] [Table 2-6] [Table 2-7] [Table 2-8] [Table 2-9] [Table 2-10]

Table 2-11

Table 2-12

Table 2-13

Table 2-14

Table 2-15

Table 2-16

Table 2-17

Table 2-18

Table 2-19

Table 2-20

Table 2-21

Table 2-22

Table 2-23

Table 2-24

Table 2-25

Table 2-26

Table 2-27

[0201] Example 2 Machine learning to predict percent target editing and specificity scores of engineered guides targeting LRRK2 mRNA. This example describes the use of machine learning to predict on-target editing (the editing percentage of the target adenosine in LRRK2 mRNA) and specificity score ((on-target editing of the target adenosine in LRRK2 mRNA) / (total off-target editing in LRRK2 mRNA)) based on an engineered guide RNA sequence. A convolutional neural network (CNN) was trained and tested using a set of 70,743 guides targeting LRRK2 mRNA, which form various structural features in the guide-target RNA scaffold. Of this guide set, 60% was used for model training and 40% was used for accuracy testing of the CNN for predicting on-target editing and specificity scores based on an engineered guide sequence. There was a high correlation between the predicted on-target editing and specificity scores and the experimentally tested on-target editing and specificity scores, indicating that the trained CNN accurately predicts on-target editing and specificity scores based on an engineered guide sequence. Experimental testing was performed in a cell-free system using a high-throughput screen of self-annealing guides linked to the target RNA by a hairpin and ADAR1 and / or ADAR2 to carry out the editing.

[0202] Example 3 Machine learning for engineered guides targeting LRRK2 mRNA This example describes the use of machine learning to generate engineered guide RNA sequences targeting LRRK2 mRNA based on the identified on-target edits and the identified specificity scores. The trained CNN of Example 2 was used in reverse to input the identified on-target edits and the identified specificity scores into the trained CNN to predict engineered guide RNA sequences with target edits and specificity scores. 768 engineered guide sequences were generated. The generated guide RNA on-target edits and specificity scores were then experimentally tested as described in Example 2 by high-throughput screening. There was a high correlation between the input identified on-target edits and specificity scores and the experimentally measured on-target edits and specificity scores, with Spearman correlation coefficients of 0.74 for on-target edits or 0.67 for specificity scores. This indicates that the trained CNN accurately generated engineered guide sequences based on the input of on-target edits and specificity scores. Exemplary engineered guide RNA sequences with high on-target edits and / or high specificity scores generated by the trained CNN are SEQ ID NO:52 to SEQ ID NO:101.

[0203] Example 4 Machine learning to determine gRNA features that affect LRRK2 mRNA editing This example describes the use of machine learning to determine the characteristics of guide RNAs that affect on-target editing and specificity scores for editing LRRK2 mRNA. A set of 1709 engineered guide RNAs was used to train and test a random forest (RF) model. Of this guide set, 1000 engineered guides were used to train the RF model, and 709 engineered guides were used to test the accuracy of the trained RF model for predicting on-target editing and specificity scores based on engineered guide sequences. There was a high correlation between the predicted on-target editing and specificity scores and the experimentally tested on-target editing and specificity scores, indicating that the trained RF model accurately predicts on-target editing and specificity scores based on engineered guide sequences. This trained RF model was then used to determine the features of the guide RNA that influence on-target editing and specificity scores, such as the length of editing time (20 seconds, 1 minute, 3 minutes, 10 minutes, 30 minutes, or 60 minutes), the ADAR used for editing (ADAR1, ADAR2, or ADAR1 and ADAR2), the position of the right barbell (relative to the target adenosine to be edited), and the position of the left barbell (relative to the target nucleotide to be edited). The right barbell position was the most important feature in predicting the specificity of the engineered guide RNA and the third most important feature in predicting on-target editing. For engineered guide RNAs that use ADAR1 for editing, the optimal position of the right barbell of the engineered guide RNA to achieve a high specificity score was +28nt or +30nt. The position is the relative position to the target adenosine in the LRRK2 mRNA to be edited. For engineered guide RNAs that use ADAR2 for editing, the optimal position of the right barbell of the engineered guide RNA to achieve a high specificity score was +24nt or +26nt, relative to the target adenosine in the LRRK2 mRNA to be edited.

[0204] Example 5 Machine learning for engineered guide RNAs targeting LRRK2 mRNA This example describes the use of machine learning to identify nucleotides at specific positions of engineered guide RNAs targeting LRRK2 mRNA that achieve high on-target editing. Machine learning was performed using a logistic regression model trained on a set of engineered guide RNAs. Logistic regression coefficients were extracted from the logistic regression model. The trained RF model of Example 4 was also used. Shapley values ​​were extracted from this trained RF model. These Shapley values ​​and logistic regression coefficients were then evaluated for overlapping nucleotides at specific positions of engineered guide RNAs with high on-target editing. This overlap was used to identify nucleotides at specific positions of engineered guide RNAs targeting LRRK2 mRNA that achieve high target editing. These nucleotides and positions in the engineered guide RNA are as follows: T at position -7, T at position -6, G at position -3, A at position -2, G at position -1, C at position 1, C at position 2, G at position 4, and T at position 10. These positions are relative to the target adenosine in the target LRRK2 mRNA that is to be edited.

[0205] Example 6 Engineered guide RNA targeting LRRK2 This example describes the on-target and off-target editing efficiencies of various engineered guide RNAs targeting the LRRK2 G2019S mutation. A side-by-side comparison of engineered guide RNAs with different structural features of the guide-target RNA scaffold formed upon hybridization of the engineered guide RNA to the target LRRK2 mRNA was evaluated in trans. Cells expressing ADAR1 were administered engineered guide RNAs in vitro. RNA editing at on-target adenosines and local off-target adenosines was evaluated by Sanger sequencing.

[0206] 5A-D show the editing profiles of four engineered guide RNAs, including an engineered guide RNA that forms an A / C mismatch structural feature at the target adenosine (FIG. 5A), an engineered guide RNA that forms an A / C mismatch structural feature at the target adenosine and a barbell at positions -20 and +26 relative to the target adenosine (position 0) (FIG. 5B), an engineered guide RNA that forms an A / G mismatch structural feature at local off-target adenosines at positions -14, -2, +10, and +13 relative to the target adenosine (position 0) (FIG. 5C), and an engineered guide RNA that forms a 1 / 0 asymmetric bulge at local off-target adenosines at positions -14, -2, +10, and +13 relative to the target adenosine (position 0) due to the deletion of U on the opposite side of the local off-target adenosine (FIG. 5D). The plots shown in Figure 5A-D indicate the position along the target RNA on the x-axis and report the percent editing on the y-axis. A diagram of the guide-target RNA scaffold for each of the engineered guide RNAs is shown immediately below each graph. As shown in Figure 5A-D, simply adding an A / G mismatch or a 1 / 0 bulge to the local off-target adenosine resulted in inhibition of on-target editing compared to the A / C mismatched engineered guide RNA. Adding a barbell macrofootprint increased on-target editing compared to the A / C mismatched engineered guide RNA.

[0207] An engineered guide RNA that forms a barbell macrofootprint at positions -14 and +22 relative to the target adenosine (position 0) and also forms a microfootprint that includes other structural features was also evaluated in cells (Figure 6). This engineered guide RNA showed enhanced on-target adenosine editing and reduced localized off-target adenosine editing compared to an A / C mismatched engineered guide RNA.

[0208] Example 7 Machine learning derived intracellular editing efficiency of LRRK2 genetically engineered guide RNA (-20, +26) This example describes the use of engineered guide RNAs of the present disclosure derived using multiple machine learning (ML) models, including exhaustive and generative ML models, to target the LRRK2 G2019S mutation in cells in vitro for editing. 750 ng of plasmid was transfected into cells (20,000 cells / well) of 68 cell line (LRRK2 cDNA minigene+ADAR1) and 219 cell line (LRRK2 cDNA minigene+ADAR1+2). Four technical replicates were performed for each engineered guide RNA. Each of the engineered guide RNAs tested contains a barbell macro footprint of symmetric internal loops and is at coordinates -20 and +26 relative to the target A.

[0209] Figures 7A-7C provide a summary of the ADAR-mediated RNA editing efficiency of each of the LRRK2 engineered guide RNAs tested. The RNA editing summaries provided in Figures 7A-7C utilized the following LRRK2 engineered guide RNAs listed in Table 3. Each of the engineered guide RNA sequences can also be represented as a DNA sequence with each U replaced with a T. [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6] [Table 3-7] [Table 3-8] [Table 3-9] [Table 3-10] [Table 3-11] [Table 3-12] [Table 3-13] [Table 3-14] [Table 3-15] [Table 3-16] [Table 3-17] [Table 3-18] [Table 3-19]

[0210] The sequences of the engineered guides used as comparisons for Figures 7A-7C are provided below in Table 4. The engineered guide RNA sequences in Table 4 are provided as DNA sequences with each U replaced with a T, however the corresponding RNA sequences are also encompassed herein. [Table 4]

[0211] Figures 8-33 show the editing efficiency of each of the engineered guide RNAs via either ADAR1 alone or ADAR1+ADAR2. Engineered guide RNAs that promoted superior editing via ADAR1 and ADAR1+ADAR2 were selected for further engineering. The following LRRK2 engineered guide RNAs listed in Table 5 correspond to the editing efficiency plots provided in Figures 8-33. The engineered guide RNA sequences in Table 5 are provided as DNA sequences with each U replaced with a T, however, the corresponding RNA sequences are also encompassed herein. [Table 5-1] [Table 5-2] [Table 5-3] [Table 5-4] [Table 5-5] [Table 5-6] [Table 5-7] [Table 5-8] [Table 5-9] [Table 5-10] [Table 5-11] [Table 5-12] [Table 5-13] [Table 5-14] [Table 5-15] [Table 5-16]

[0212] Figure 34A and Figure 34B show a selection of two exemplary engineered guide RNAs showing superior editing that were selected for further engineering.

[0213] Of note, the machine learning algorithm accurately predicted ADAR specificity. As shown in Figure 35, guide RNAs selected for ADAR1, ADAR2, or ADAR1 and ADAR2 showed specificity for the appropriate ADAR enzyme in vitro. Figure 36 shows the design of engineered guide RNAs that showed specificity for ADAR2 in Figure 35. In this system, engineered guide RNAs designed to form AG mismatches at the target adenosine were shown to promote preferential RNA editing by ADAR2.

[0214] Figures 37A and 37B show the top engineered guide RNAs that show specificity for ADAR1+ADAR2. Figures 38A and 38B show the top engineered guide RNAs that show specificity for ADAR2. Figures 39A and 39B show the top engineered guide RNAs that show specificity for ADAR1.

[0215] Example 8 ML gRNA targeting LRRK2 This example describes machine learning (ML)-derived gRNAs targeting LRRK2. Two types of machine learning models, generative and exhaustive, were used to design and then evaluate LRRK2 gRNAs. Next-generation sequencing (NGS) was used to compare the highly efficient and specific ML-derived gRNAs with gRNAs generated using in vitro high-throughput screening (HTS) methods. The gRNAs were administered to HEK293 cells expressing LRRK2 cDNA minigenes. Two generative ML gRNAs in particular leveraged ADARs to promote highly efficient and specific RNA editing (Figure 27 - CCCTGGTGTGCCCTCTGATGTTTTTTAGGGGATTCTACAGGAGGACTGGGCAGTCCCGTGGTCGCCCTTCTTTGCATACTACGCAGCATTGGGATACAGTGTGAAAAGCAGCA (SEQ ID NO: 201), Figure 19 - CCCTGGTGTGCCCTCTGATGTTTTTTAGGGGATTCTACAGCAGTACTGTCCAGTCCCGTGGTCGTAAATCTTTGCATACTACGCAGCATTGGGATACAGTGTGAAAAGCAGCA (SEQ ID NO: 202), and Figure 40).

[0216] Additionally, gRNAs that preferentially utilize ADAR2 for RNA editing are also disclosed herein (e.g., FIG. 17-CCCTGGTGTGCCCTCTGATGTTTTTTAGGGGATTCTACAGCACGACTGAGCAGTGCGTTAGTCGGCAATCTTTGCATACTACGCAGCATTGGGATACAGTGTGAAAAGCAGCA (SEQ ID NO: 203)). FIG. 35 shows a plot of on-target editing rate (%) of ADAR1+2 (x-axis) versus on-target editing rate (%) of ADAR1 only (y-axis). As shown in this figure, some gRNAs of the present disclosure that contain AG mismatches (guide-target RNA scaffold structure shown in FIG. 36) show ADAR2 preference. Thus, an AG mismatch in target A may potentially induce ADAR2-specific editing.

[0217] Example 9 Engineering LRRK2 guide RNAs selected using HTS This example describes the engineering of guide RNAs using high-throughput screening (see Example 1) to target the LRRK2 G2019S mutation for RNA editing by ADAR. Figure 41 provides an overview of the engineering process. As shown in Figure 41, the engineering process includes: 1. positioning the macro footprint; 2. fine-tuning the left and right barbell coordinates; and 3. shortening the guide length. LRRK2 guide RNA count 610 (-14, 26) - SEQ ID NO: 5, count 871 (-16, 24) - SEQ ID NO: 23, and count 919 (-12, 24) - SEQ ID NO: 50 were selected for further engineering.

[0218] Adding a barbell macro footprint formed on the guide-target RNA scaffold increases on-target adenosine editing relative to the amount of off-target editing. As shown in Figures 42A and 42B, guide 610 (which upon hybridization to the target RNA forms a barbell macro footprint with barbells at positions -14 and +26) showed reduced off-target editing of both ADAR1 and ADAR1+ADAR2 compared to the same engineered guide RNA lacking the potential structure that results in a barbell macro footprint upon hybridization to the target RNA.

[0219] Figures 43A-C show the first step in the guide 610 design process: macrofootprint positioning. Figure 43A shows the alignment of macrofootprint positions within the guide-target RNA scaffold of guide 610 relative to the A / C mismatch and how this alignment affects RNA editing by ADAR1 and ADAR1+ADAR2. Figure 43B shows the percent editing of the ADAR1-mediated aligned guide 610 variants. As previously described, an engineered guide RNA with a mismatch located 60 nucleotides (0.100.60) from the end of the guide and showing 36% LRRK2 editing was selected for further engineering. Figure 43C shows the percent editing of the ADAR1+ADAR2-mediated aligned guide 610 variants. As previously described, an engineered guide RNA with a mismatch located 60 nucleotides (0.100.60) from the end of the engineered guide RNA and showing 58% LRRK2 editing was selected for further engineering.

[0220] The 0.100.60 guide 610 was carried forward to the next design step, fine-tuning the left and right barbell coordinates. Figures 44A-C show the engineering of the right barbell coordinates. As shown in Figure 44A, the coordinates of the right barbell were aligned between +22, +23, +24, +25, +26, +28, +30, +32, and +34 coordinates relative to the A / C mismatch to determine the impact of each position on ADAR1 and ADAR1+ADAR2 editing. Figure 44B shows the percent editing of the position-aligned guide 610 variants via ADAR1. As previously mentioned, the guide containing the right barbell at position +34 (relative to the A / C mismatch) and showing 41% LRRK2 editing was selected for further engineering. Figure 44C shows the percent editing of the position-aligned guide 610 variants via ADAR1+ADAR2. As previously described, guides containing the right barbell at position +34 (relative to the A / C mismatch) and indicating 50% ADAR-mediated LRRK2 editing were selected for further genetic manipulation.

[0221] The 0.100.60 guide 610 with a right barbell at position +34 (relative to the A / C mismatch) was used as the starting scaffold for the alignment of the left barbell coordinates. Figures 45A and 45B show the engineering of the left barbell coordinates. As shown in Figure 45A, the coordinates of the left barbell were aligned between the coordinates of -10, -12, -14, -16, -18, -20, -22, and -24 relative to the A / C mismatch to determine the influence of each position on ADAR1 and ADAR1+ADAR2 editing. Figure 45B shows the editing percentage of the aligned guide 610 variants via ADAR1. As mentioned above, the guide containing the left barbell at position -10 and the right barbell at position +34 (relative to the A / C mismatch) and showing 50% ADAR-mediated LRRK2 editing was selected for further engineering.

[0222] The guide 610 variant with the barbell at coordinates (-10, +34) was then subjected to the third stage of design: shortening the guide length. Figures 46A and 46B show the engineering of guide length. As shown in Figure 46A, the impact of each guide length on ADAR1 and ADAR1+ADAR2 editing was determined. Figure 46B shows the percent editing of guide 610 variants of various lengths through ADAR1. As mentioned above, an engineered guide RNA that is 92 nt long, has a mismatch located 60 nt (0.92.60) from the end of the guide, and shows 60% LRRK2 editing was selected as the top guide. Table 6 below lists the sequences of the engineered guide 610 RNAs shown in Figures 42A-46B. The engineered guide RNA sequences in Table 6 are provided as DNA sequences with each U replaced with a T, but the corresponding RNA sequences are also encompassed herein. [Table 6-1] [Table 6-2] [Table 6-3] [Table 6-4] [Table 6-5] [Table 6-6] [Table 6-7] [Table 6-8] [Table 6-9] [Table 6-10] [Table 6-11] [Table 6-12] [Table 6-13]

[0223] Figures 47-77 show the engineering of LRRK2 variants selected by high throughput screening, as described above for guide 610. Table 7 below lists the sequences of the engineered guide RNAs shown in Figures 47-77. The engineered guide RNA sequences in Table 7 are provided as DNA sequences with each U replaced with a T, however, the corresponding RNA sequences are also encompassed herein. [Table 7-1] [Table 7-2] [Table 7-3] [Table 7-4]

Table 7-5

Table 7-6

Table 7-7

Table 7-8

Table 7-9

Table 7-10

Table 7-11

Table 7-12

Table 7-13

Table 7-14

Table 7-15

Table 7-16

Table 7-17

Table 7-18

Table 7-19

Table 7-20

Table 7-21

Table 7-22

Table 7-23

Table 7-24

Table 7-25

Table 7-26

Table 7-27

Table 7-28

Table 7-29

Table 7-30

Table 7-31

Table 7-32

Table 7-33

Table 7-34

Table 7-35

Table 7-36

Table 7-37

Table 7-38

[0224] As shown in Figure 77, engineering of guide 610, guide 871 and guide 919 resulted in a large increase in editing efficiency. Thus, this example shows that guide RNAs against LRRK2 selected by high-throughput screening can be systematically engineered to dramatically increase their editing efficiency by modulating the position of the barbell macrofootprint within the guide-target RNA scaffold.

[0225] Example 10 In vitro screening of selected LRRK2 gRNAs using HTS This example describes the construction of scAAV vectors for in vitro screening of LRRK2 engineered guide RNAs selected using high throughput screening (see Example 1) and / or engineered as described in Example 9. In this example, counts 919(-14,22)-SEQ ID NO:354, counts 871(-16,32)-SEQ ID NO:312, counts 2397(-14,28)-SEQ ID NO:351, counts 610(-14,34)-SEQ ID NO:228, and counts 1976(-22,26)-SEQ ID NO:369 were evaluated.

[0226] Each engineered guide RNA was cloned into a scAAV vector, as shown in Figure 78. Each guide is flanked by the human U1 promoter (TAAGGACCAGCTTCTTTGGGAGAGAACAGACGCAGGGGCGGGAGGGAAAAAGGGAGAGGCAGACGTCACTTCCTCTTGGCGACTCTGGCAGCAGATTGGTCGGTTGAGTGGCAGAAAGGCAGACGGGGACTGGGCAAGGCACTGTCGGTGACATCACGGACAGGGCGACTTCTATGTAGATGAGGCAGCGCAGAGGCTGCTGCTTCGCCACTTGCTGCTTCGCCACGAAGGGAGTTCCCGTGCCCTGGGAGCGGGTTCAGGACCGCTGATCGGAAGTGAGAATCCCAGCTGTGTGTCAGGGCTGGAAAGGGCTCGGGAGTGCGCGGGGCAAGTGACCGTGTGTGTAAAGAGTGAGGCGTATGAGGCTGTGTCGGGGCAGAGCCCGAAGATCTC) - SEQ ID NO: 396 and the SmOPT sequence (AATTTTTGGAG) - SEQ ID NO: 397. Each vector was transfected into HEK293 cells, and the percent RNA editing promoted by each engineered guide RNA via ADAR1+ADAR2 was compared to the control. As shown in Figure 79A, each of the transfected engineered guide RNAs promoted higher levels of editing compared to the control. Each variant was then packaged into scAAV virus, and the ability of each guide to promote ADAR1+ADAR2-mediated editing after transduction was determined. As shown in Figure 79B, each guide RNA showed similar editing when packaged into scAAV virus via transduction as when transfected as an AAV plasmid. After differentiation, all cell lines selected as LRRK2 in vitro models show key features of neuronal development, including neurite extension and cell-cell connections. Thus, this example shows that transfection of scAAV vectors containing engineered guide RNAs restores neuronal development in an in vitro cell model.

[0227] Example 11 Editing LRRK2 with engineered guide RNAs using a broken GFP reporter 100 nucleotide engineered guide RNAs containing A / C mismatches at positions 25, 50, and 75 and LRRK2 guide mimics or barbells at different positions were tested in K562 cells expressing a GFP-G67R reporter. Figure 80 shows a workflow for screening exemplary guide RNAs targeting LRRK2 in the broken GFP reporter system. Cells were selected with puromycin to enrich for plasmid and guide integration. WT ADAR results were obtained from cells captured after 14 days of puromycin selection, and for ADAR2 overexpression (with the weak constitutive promoter PGK) from cells captured after 21 days of selection. Editing was assessed by NGS sequencing on an iSeq instrument.

[0228] Table 8 below lists the engineered guide RNA sequences utilized in this example. The engineered guide RNA sequences in Table 8 are provided as DNA sequences with each U replaced with a T, however, the corresponding RNA sequences are also encompassed herein. [Table 8-1] [Table 8-2]

[0229] Figure 81 shows the editing efficiency of exemplary guides targeting LRRK2 via exogenous or endogenous ADARs in a broken GFP reporter system.

[0230] Example 12 Editing efficiency of circularized exemplary engineered guide RNAs targeting LRRK2 HEK cells expressing endogenous ADAR and LRRK2 minigenes were utilized for these experiments. Specifically, 20,000 cells were transfected with 750 ng of plasmid and 3 μL of Trans-IT 293 by reverse transfection. Cells were harvested 48 hours after transfection. All linear gRNAs were expressed in a plasmid-encoded U1 SmOpt format. All circular gRNAs were generated by flanking the antisense sequence with a ribozyme expressed from a U6 promoter in a plasmid-encoded format.

[0231] Table 9 below contains the sequences of the engineered guide RNAs used in this example. The underlined nucleotides in the circular gRNA represent the ribozyme, ligation stem, and golden gate scar.

[0232] [Table 9-1] [Table 9-2] [Table 9-3] [Table 9-4]

[0233] Figure 82 provides a comparison between the linear and circularized versions of exemplary guide RNA guide 871 and guide 919 targeting LRRK2. The editing efficiency of the circularized version of the guide RNA was lower than the linear one, but the editing efficiency increased when the circularized guide RNA was lengthened by an additional 15 nucleotides (Figure 83A), 30 nucleotides (Figure 83A), and 100 nucleotides (Figure 83B). Finally, selected uridines were deleted from the circularized guide 919 to generate U deletion variants. The effect of U deletion on editing is shown in Figure 84.

[0234] Example 13 In vivo efficiency of AAV vectors encoding engineered guide RNAs targeting LRRK2 The scAAV vector constructed in Example 9 was utilized in this example. Following QC validation of on-target LRRK2 G2019S editing and guide expression, the scAAV vector was packaged into scAAVDJ virus for in vivo testing in LRRK2 G2019S transgenic mice.

[0235] Experimental animals

[0236] Hemizygous BAC LRRK2 G2019S transgenic mice were utilized in this example (C57BL / 6J-Tg(LRRK2*G2019S)2AMjff / J; strain #018785).

[0237] Thy1.1 enrichment

[0238] Brain (ICV) and liver (IV) tissue samples from experimental mice were dissected and dissociated into single-cell suspensions using a gentleMACS Dissociator (Miltenyi Biotec). After dissociation, an aliquot of each sample was set aside and designated "pre-enrichment." The remainder of the samples were enriched for Thy1.1-expressing cells by MACS using CD90.1 MicroBeads (Miltenyi Biotec; catalog no. 130-121-273) and designated "post-enrichment."

[0239] Sanger sequencing / EditADAR analysis

[0240] RNA extraction of "pre-enriched" and "post-enriched" brain and liver samples was performed using the mirVana™ miRNA Isolation Kit (ThermoFisher) according to the manufacturer's protocol. cDNA synthesis was performed using the ProtoScript® II First Strand cDNA Synthesis Kit (NEB) according to the manufacturer's protocol. PCR amplification of the LRRK2 G2019S target locus was performed using Q5® High-Fidelity 2x Master Mix (NEB) with the following specific primers and thermocycler settings: [Table 10]

[0241] Following PCR amplification and gel confirmation of specific products, ExoSAP-IT™ PCR product clean-up reagent (ThermoFisher) was added to the samples before sending for Sanger sequencing. Sequencing trace files (.ab1) were analyzed by EditADAR (ShapeTX) to generate RNA editing profiles.

[0242] ddPCR guide RNA quantification

[0243] cDNA synthesis of "pre-enriched" and "enriched" brain and liver RNA samples was performed using the ProtoScript® II First Strand cDNA Synthesis Kit (NEB) according to the manufacturer's protocol with the modification of using a smOPT specific primer (5'-CAGAAAACCTGCTCCAAAAATTCCAC-3') and oligo d(T)23VN in a 1:1 ratio. ddPCR was performed on a QX200 system (Bio-Rad) using ddPCR Supermix for Probes (without dUTP) (Bio-Rad; catalog no. 1863024) with the following specific ddPCR primers and probes and thermocycler settings: [Table 11]

[0244] ddPCR absolute values ​​of engineered guide RNA and GAPDH were recorded as copies / uL. Guide RNA copy numbers were normalized to GAPDH copy numbers. Figure 85A and Figure 85C show the in vivo editing efficiency of scAAV vectors encoding engineered guide RNAs targeting LRRK2 measured in brain (Figure 85A) and liver (Figure 85C). No detectable editing was observed in mouse brain or liver tissues ICV-injected with scAAVDJ-engineered guide RNA. EditADAR analysis and representative Sanger sequencing traces from brain RNA samples of no treatment, pre-Thy1.1 enriched scAAVDJ-engineered guide RNA and post-Thy1.1 enriched scAAVDJ-engineered guide RNA. Figure 85B and Figure 85D show quantification of engineered guide RNA expression relative to GAPDH control expression in brain (Figure 85B) and liver (Figure 85D). Low levels of guide RNA expression were detected in both pre- and post-Thy1.1 enriched brain and liver samples (<1 guide RNA copy per GAPDH) as measured by ddPCR analysis.

[0245] While preferred embodiments of the present disclosure have been shown and described herein, such embodiments are provided by way of example only. Numerous variations, changes, and substitutions can be made without departing from the present disclosure. It will be understood that various alternatives to the embodiments described herein may be employed.

Claims

1. An engineered potential guide RNA, (a) upon hybridization to a sequence of a target LRRK2 RNA, forms a guide-target RNA scaffold with said sequence of the target LRRK2 RNA; (b) formation of the guide-target RNA scaffold substantially forms a microfootprint comprising one or more structural features selected from the group consisting of a mismatch, a bulge, an internal loop, and a hairpin; (c) the structural feature is not present in the engineered potential guide RNA prior to hybridization of the engineered potential guide RNA to the LRRK2 target RNA; (d) upon hybridization of the engineered potential guide RNA to the sequence of the target LRRK2 RNA, the engineered potential guide RNA promotes RNA editing of an on-target adenosine in the sequence of the target LRRK2 RNA by an RNA editing entity; (e) the engineered potential guide RNA has at least 80%, at least 85%, at least 90%, at least 92%, at least 95%, at least 99%, or 100% sequence identity to any one of SEQ ID NOs:2-395 or SEQ ID NOs:398-427.

2. 2. The engineered potential guide RNA of claim 1, wherein the engineered potential guide RNA comprises a polynucleotide sequence of any one of SEQ ID NOs:2-395 or SEQ ID NOs:398-427.

3. 2. The engineered potential guide RNA of claim 1, wherein the engineered potential guide RNA comprises at least 20-50 contiguous nucleotides from a portion of any one of SEQ ID NOs:2-395 or SEQ ID NOs:398-427.

4. 4. The engineered potential guide RNA of any one of claims 1 to 3, wherein the sequence further comprises one or more of the following: T at position -7, T at position -6, G at position -3, A at position -2, G at position -1, C at position 1, C at position 2, T at position 3, G at position 4, and T at position 10, wherein these positions are relative to a target adenosine in the sequence of a target LRRK2 RNA that is subject to editing by an RNA editing entity.

5. 5. The engineered potential guide RNA of any one of claims 1 to 4, wherein the engineered potential guide RNA comprises a cytosine that is opposite the target adenosine edited by the RNA editing entity in the guide-target RNA scaffold when the engineered potential guide RNA hybridizes to the target RNA, thereby forming an A / C mismatch in the guide-target RNA scaffold.

6. 6. The engineered potential guide RNA of claim 5, wherein the guide-target RNA scaffold comprises a barbell macrofootprint including a first internal loop and a second internal loop adjacent opposite ends of the microfootprint, the first internal loop being on the 5' side of the microfootprint and the second internal loop being on the 3' side of the microfootprint, wherein the first internal loop and the second internal loop promote an increased amount of editing of the target adenosine in the target RNA relative to an otherwise equivalent engineered guide RNA lacking the first internal loop and the second internal loop.

7. 7. The engineered potential guide RNA of Claim 6, wherein the first internal loop is positioned, with respect to a base of the first internal loop closest to the A / C mismatch, from about 7 bases away from the A / C mismatch to about 30 bases away from the A / C mismatch.

8. 8. The engineered potential guide RNA of Claim 7, wherein the first internal loop is positioned 10 bases away from the A / C mismatch with respect to a base of the first internal loop closest to the A / C mismatch.

9. 9. The engineered potential guide RNA of any one of claims 6-8, wherein the second internal loop is positioned, with respect to a base of the second internal loop closest to the A / C mismatch, from about 18 bases away from the A / C mismatch to about 34 bases away from the A / C mismatch.

10. 10. The engineered potential guide RNA of Claim 9, wherein the second internal loop is positioned 34 bases away from the A / C mismatch with respect to a base of the second internal loop closest to the A / C mismatch.

11. The target LRRK2 RNA encodes an LRRK2 polypeptide having a mutation relative to a wild-type LRRK2 polypeptide, the mutations being E10L, A30P, S52F, E46K, A53T, L119P, A211V, C228S, E334K, N363S, V366M, A419V, R506Q, N544E, N551K, A716V, M712V, I723V , P755L, R793M, I810V, K871E, Q923H, Q930R, R1067Q, S1096C, Q1111H, I1122V, A1151T, L1165 P, I1192V, H1216R, S1228T, P1262A, R1325Q, I1371V, R1398H, T1410M, D1420N, R1441G, R1441 H, A1442P, P1446L, V1450I, K1468E, R1483Q, R1514Q, P1542S, V1613A, R1628P, M1646T, S1647 T, Y1699C, R1728H, R1728L, L1795F, M1869V, M1869T, L1870F, E1874X, R1941H, Y2006H, I2012 11. The engineered potential guide RNA of any one of claims 1 to 10, selected from the group consisting of T, G2019S, I2020T, T2031S, N2081D, T2141M, R2143H, Y2189C, T2356I, G2385R, V2390M, E2395K, M2397T, L2466H, and Q2490NfsX3.

12. 12. The engineered potential guide RNA of claim 11 , wherein the mutation is a G2019S mutation.

13. 13. The engineered potential guide RNA of any one of claims 1 to 12, wherein the one or more structural features of the microfootprint comprise a bulge, and the bulge is a symmetric bulge.

14. 13. The engineered potential guide RNA of any one of claims 1 to 12, wherein the one or more structural features of the microfootprint comprise a bulge, and the bulge is an asymmetric bulge.

15. 13. The engineered potential guide RNA of any one of claims 1 to 12, wherein the one or more structural features of the microfootprint comprise an internal loop, and the internal loop is a symmetric internal loop.

16. 13. The engineered potential guide RNA of any one of claims 1 to 12, wherein the one or more structural features of the microfootprint comprise an internal loop, and the internal loop is an asymmetric internal loop.

17. 13. The engineered potential guide RNA of any one of claims 1 to 12, wherein the one or more structural features of the microfootprint comprise wobble base pairs.

18. 13. The engineered potential guide RNA of any one of claims 1 to 12, wherein the one or more structural features of the microfootprint comprise a hairpin, and the hairpin is a recruitment hairpin or a non-recruitment hairpin.

19. 19. The engineered potential guide RNA of any one of claims 1 to 18, wherein the RNA editing entity comprises ADAR1, ADAR2, ADAR3, or any combination thereof.

20. 20. The engineered potential guide RNA of any one of claims 1 to 19, wherein the engineered potential guide RNA is encoded by an engineered polynucleotide.

21. 21. The engineered potential guide RNA of claim 20, wherein the engineered polynucleotide is contained in or present on a vector.

22. 22. The engineered potential guide RNA of claim 21 , wherein the vector is a viral vector and the engineered polynucleotide is encapsidated by the viral vector.

23. 23. The engineered potential guide RNA of claim 22, wherein the viral vector is an adeno-associated viral (AAV) vector or a derivative thereof.

24. 24. The engineered potential guide RNA of claim 23, wherein the AAV vector is AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, or a derivative, chimera, or variant thereof.

25. 24. The engineered potential guide RNA of claim 22 or 23, wherein the AAV vector is a recombinant AAV (rAAV) vector, a hybrid AAV vector, a chimeric AAV vector, a self-complementary AAV (scAAV) vector, or any combination thereof.

26. (a) an engineered potential guide RNA according to any one of claims 1 to 25; (b) a pharma- ceutically acceptable excipient, carrier, or diluent; 13. A pharmaceutical composition comprising:

27. A method of treating a disease or condition in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an engineered potential guide RNA according to any one of claims 1 to 25 or a pharmaceutical composition according to claim 26.

28. 28. The method of claim 27, wherein the disease or condition comprises Parkinson's disease.

29. 28. The method of claim 27, wherein the disease or condition comprises Crohn's disease.

30. The subject is E10L, A30P, S52F, E46K, A53T, L119P, A211V, C228S, E334K, N363S, V366M, A419V, R506Q, N544E, N551K, A716V, M712V, I723V, P755L, R793M, I810V, K871E, Q923H, Q9 30R, R1067Q, S1096C, Q1111H, I1122V, A1151T, L1165P, I1192V, H1216R, S1228T, P126 2A, R1325Q, I1371V, R1398H, T1410M, D1420N, R1441G, R1441H, A1442P, P1446L, V1450 I, K1468E, R1483Q, R1514Q, P1542S, V1613A, R1628P, M1646T, S1647T, Y1699C, R1728H , R1728L, L1795F, M1869V, M1869T, L1870F, E1874X, R1941H, Y2006H, I2012T, G2019S, 28. The method of claim 27, having a mutation in the LRRK2 polypeptide selected from the group consisting of I2020T, T2031S, N2081D, T2141M, R2143H, Y2189C, T2356I, G2385R, V2390M, E2395K, M2397T, L2466H, and Q2490NfsX3.

31. 31. The method of claim 30, wherein the mutation in the LRRK2 polypeptide is associated with the disease or condition.

32. 31. The method of claim 30, wherein the mutation in the LRRK2 polypeptide is G2019S.

33. The method of any one of claims 27 to 32, wherein the subject is a human or a non-human animal.